# EDGAR Filing Document

**Accession Number:** 0001539337
**File Stem:** 0001999371-26-001801
**Filing Date:** 2026-1
**Character Count:** 233502
**Document Hash:** 4681c19634d68c56e2f5524459ebc905
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-26-001801.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001999371-26-001801

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260127

**DATE AS OF CHANGE**: 20260127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nuveen Real Asset Income & Growth Fund
- **CENTRAL INDEX KEY:** 0001539337

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291585
- **FILM NUMBER:** 26566171

**BUSINESS ADDRESS:**
- **STREET 1:** 333 W. WACKER DR.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 312-917-8146

**MAIL ADDRESS:**
- **STREET 1:** 333 W. WACKER DR.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

?xml version='1.0' encoding='ASCII'?

**Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-291585**

![](nuveenlogo.jpg)

**PROSPECTUS SUPPLEMENT**

**(To Prospectus dated January 23, 2026)**

**Up to 28,000,000 Rights for Up to 7,000,000 Common Shares**

**Issuable Upon the Exercise of** 

**Transferable Subscription Rights to Purchase Common Shares**

**Nuveen Real Asset Income and Growth Fund**

Nuveen Real Asset Income and Growth Fund (the "Fund"), a diversified, closed-end management investment company, is issuing up to 28,000,000 transferable subscription rights (the "Rights") to its common shareholders (the "Common Shareholders") to subscribe for an aggregate of up to 7,000,000 common shares, $0.01 par value per share (each, a "Common Share," and collectively, the "Common Shares"), pursuant to this prospectus supplement. The actual number of Rights and Common Shares issued will be based upon the total number of Common Shares outstanding as of the Record Date (as defined below), which will be impacted by certain events, such as the issuance of new Common Shares pursuant to the Fund's dividend reinvestment plan.

Common Shares are listed on the New York Stock Exchange (the "NYSE") under the symbol "JRI." Common Shareholders of record on February 6, 2026 (the "Record Date") will receive one Right for each Common Share held. These Rights are transferable and will allow the holders thereof to purchase additional Common Shares. The Rights will be listed for trading on the NYSE under the symbol "JRI RT" during the course of the Rights offering.

The Rights entitle the holders to purchase one new Common Share for every four Rights held (1 for 4) (the "Primary Subscription"). Record Date Common Shareholders ("Record Date Shareholders") who fully exercise their Rights will be entitled to over-subscribe for additional Common Shares covered by any unexercised Rights in the Primary Subscription, subject to certain limitations and subject to allotment. In addition, the Fund, subject to approval by the Board of Trustees of the Fund (the "Board"), may increase the number of Common Shares available for subscription by up to 25%, or up to an additional 1,750,000 Common Shares, for an aggregate total of up to 8,750,000 Common Shares. See "Description of the Rights Offering—Primary and Secondary Over-Subscription Privileges." Fractional shares will not be issued upon exercise of Rights. Accordingly, Common Shares may be purchased only pursuant to the exercise of Rights in integral multiples of four. The number of Rights issued to a Record Date Shareholder will be rounded up to the nearest number of Rights evenly divisible by four.

The subscription price per Common Share (the "Subscription Price") will be determined based upon a formula equal to 95% of the average of the last reported sales price of the Common Shares on the NYSE on the Expiration Date (as defined below) and each of the four (4) preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 90% of the net asset value ("NAV") per Common Share at the close of trading on the NYSE on the Expiration Date, then the Subscription Price will be 90% of the Fund's NAV per Common Share at the close of trading on the NYSE on the Expiration Date. The Rights offering will expire at 5:00 p.m., Eastern Time, on March 9, 2026 (the "Expiration Date").

---

| | | |
|:---|:---|:---|
|  | **Per Common**<br> **Share** | **Total<sup>(1)</sup>** |
| Estimated subscription price of Common Shares to shareholders exercising Rights<sup>(2)</sup> | $12.99 | $90930000 |
| Estimated sales load |  |  |
| Estimated proceeds, before expenses, to the Fund<sup>(3)</sup> | $12.99 | $90930000 |

---

<sup>(1)</sup> Assumes that all Rights are exercised at the estimated Subscription Price (as described below). All of the Rights may not be exercised, and the estimated Subscription Price may be higher or lower than the actual Subscription Price.

<sup>(2)</sup> The estimated Subscription Price to the public is based upon 95% of the average of the last reported sales price of the Fund's Common Shares on the NYSE on January 21, 2026 and each of the four (4) preceding trading days. See "Terms of the Rights Offering—Subscription Price."

<sup>(3)</sup> Nuveen Fund Advisors, LLC ("Nuveen Fund Advisors"), and not the Fund or its Common Shareholders, will bear all expenses incurred in connection with the Rights offering. Offering expenses borne by Nuveen Fund Advisors are estimated to be approximately $400,000 in the aggregate.

*(continued on next page)*

*(continued from previous page)*

 

The Common Shares are expected to be ready for delivery in book-entry form through the Depository Trust Company on or about March 16, 2026, unless extended.

The closing price for the Common Shares on the NYSE on January 21, 2026 was $13.72. The NAV of the Common Shares at the close of business on January 21, 2026 was $13.57 per Common Share.

**Investing in the Common Shares through Rights involves risks. See "Risk Factors" beginning on page 14 of the accompanying prospectus and "Special Characteristics and Risks of the Rights Offering" beginning on page 21 in this prospectus supplement. You should consider carefully these risks together with all of the other information in this prospectus supplement and the accompanying prospectus before making a decision to invest in Common Shares through Rights.**

**SHAREHOLDERS WHO DO NOT FULLY EXERCISE THEIR RIGHTS MAY, AT THE COMPLETION OF THE RIGHTS OFFERING, OWN A SMALLER PROPORTIONAL INTEREST IN THE FUND THAN IF THEY EXERCISED THEIR RIGHTS. AS A RESULT OF THE RIGHTS OFFERING YOU MAY EXPERIENCE SUBSTANTIAL DILUTION OF THE AGGREGATE NET ASSET VALUE OF YOUR COMMON SHARES. ALL COSTS OF THE OFFERING WILL BE BORNE BY NUVEEN FUND ADVISORS, AND NOT THE FUND OR COMMON SHAREHOLDERS. RIGHTS EXERCISED BY A RIGHTS HOLDER ARE IRREVOCABLE.**

**THE FUND HAS DECLARED MONTHLY OR EXPECTS TO DECLARE DISTRIBUTIONS PAYABLE ON MARCH 2, 2026 AND APRIL 1, 2026, WITH RECORD DATES OF FEBRUARY 13, 2026 AND MARCH 2, 2026, RESPECTIVELY. ANY COMMON SHARES ISSUED AFTER SUCH RECORD DATES AS A RESULT OF THE RIGHTS OFFERING WILL NOT BE RECORD DATE COMMON SHARES FOR THE FUND'S MONTHLY DISTRIBUTIONS TO BE PAID ON MARCH 2, 2026 AND APRIL 1, 2026 AND WILL NOT BE ENTITLED TO RECEIVE SUCH DISTRIBUTIONS.**

**The date of this prospectus supplement is January 27, 2026.**

You should read this prospectus supplement, together with the accompanying prospectus, which contains important information about the Fund, before deciding whether to invest in Common Shares through Rights and retain it for future reference. A [statement of additional information](https://www.sec.gov/ix?doc=/Archives/edgar/data/1539337/000199937126001398/jri-n2a_012126.htm#toc780884_24), dated January 23, 2026, and as it may be supplemented (the "SAI"), containing additional information about the Fund, has been filed with the SEC and is incorporated by reference in its entirety into this prospectus supplement and the accompanying prospectus. This prospectus supplement, the accompanying prospectus and the SAI are part of a "shelf" registration statement filed with the SEC. This prospectus supplement describes the specific details regarding this offering. If information in this prospectus supplement is inconsistent with the accompanying prospectus or the SAI, you should rely on this prospectus supplement. You may request a free copy of the SAI, annual and semi-annual reports to shareholders, and other information about the Fund, and make shareholder inquiries by calling (800) 257-8787 or by writing to the Fund at 333 West Wacker Drive, Chicago, Illinois 60606, or from the Fund's website (www.nuveen.com). The information contained in, or that can be accessed through, the Fund's website is not part of this prospectus supplement, the accompanying prospectus or the SAI, except to the extent specifically incorporated by reference herein. You also may obtain a copy of the SAI (and other information regarding the Fund) from the SEC's website (www.sec.gov).

You should not construe the contents of this prospectus supplement and the accompanying prospectus as legal, tax or financial advice. You should consult with your own professional advisors as to the legal, tax, financial or other matters relevant to the suitability of an investment in the Common Shares through Rights.

**Common Shares do not represent a deposit or obligation of, and are not guaranteed or endorsed by, any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency.**

**Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.**

**TABLE OF CONTENTS**

**Prospectus Supplement**

---

| | |
|:---|:---|
|  | **Page** |
| [Forward-Looking Statements](#supp_001) | ii |
| [Prospectus Supplement Summary](#supp_002) | S-1 |
| [Description of the Rights Offering](#supp_003) | S-6 |
| [Summary of Fund Expenses](#supp_004) | S-16 |
| [Trading and Net Asset Value Information](#supp_005) | S-18 |
| [Use of Proceeds](#supp_006) | S-18 |
| [Capitalization](#supp_007) | S-19 |
| [Special Characteristics and Risks of the Rights Offering](#supp_008) | S-20 |
| [Taxation](#supp_009) | S-23 |
| [Legal Matters](#supp_010) | S-24 |
| [Available Information](#supp_011) | S-24 |

---

**Prospectus**

---

| | |
|:---|:---|
| [Prospectus Summary](#toc780884_1) | 1 |
| [Summary of Fund Expenses](#toc780884_2) | 7 |
| [Financial Highlights](#toc780884_3) | 8 |
| [Trading and Net Asset Value Information](#toc780884_4) | 9 |
| [The Fund](#toc780884_5) | 9 |
| [Use of Proceeds](#toc780884_6) | 10 |
| [The Fund's Investments](#toc780884_7) | 10 |
| [Use of Leverage](#toc780884_8) | 11 |
| [Risk Factors](#toc780884_9) | 14 |
| [Management of the Fund](#toc780884_10) | 14 |
| [Net Asset Value](#toc780884_11) | 17 |
| [Distributions](#toc780884_12) | 17 |
| [Dividend Reinvestment Plan](#toc780884_13) | 18 |
| [Plan of Distribution](#toc780884_14) | 18 |
| [Description of Shares](#toc780884_15) | 21 |
| [Rights Offerings](#toc780884_16) | 24 |
| [Certain Provisions in the Declaration of Trust and By-Laws](#toc780884_17) | 25 |
| [Repurchase of Fund Shares; Conversion to Open-End Fund](#toc780884_18) | 27 |
| [Tax Matters](#toc780884_19) | 28 |
| [Custodian and Transfer Agent](#toc780884_20) | 29 |
| [Independent Registered Public Accounting Firm](#toc780884_21) | 30 |
| [Legal Matters](#toc780884_22) | 30 |
| [Available Information](#toc780884_23) | 30 |
| [Incorporation By Reference](#toc780884_24) | 30 |

---

**You should rely only on the information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus. The Fund has not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The Fund is not making an offer of Common Shares in any state where the offer is not permitted. You should not assume that the information contained in this prospectus supplement and the accompanying prospectus is accurate as of any date other than the respective dates on the front covers. The Fund's business, financial condition and prospects may have changed since that date.**

i

**FORWARD-LOOKING STATEMENTS**

Any projections, forecasts and estimates contained or incorporated by reference herein are forward looking statements and are based upon certain assumptions. Projections, forecasts and estimates are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any projections, forecasts or estimates will not materialize or will vary significantly from actual results. Actual results may vary from any projections, forecasts and estimates and the variations may be material. Some important factors that could cause actual results to differ materially from those in any forward-looking statements include changes in interest rates, market, financial or legal uncertainties, including changes in tax law, and the timing and frequency of defaults on underlying investments. Consequently, the inclusion of any projections, forecasts and estimates herein should not be regarded as a representation by the Fund or any of its affiliates or any other person or entity of the results that will actually be achieved by the Fund. Neither the Fund nor its affiliates has any obligation to update or otherwise revise any projections, forecasts and estimates including any revisions to reflect changes in economic conditions or other circumstances arising after the date hereof or to reflect the occurrence of unanticipated events, even if the underlying assumptions do not come to fruition. The Fund acknowledges that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as the Fund.

ii

**PROSPECTUS SUPPLEMENT SUMMARY**

*This is only a summary. You should review the more detailed information contained elsewhere in this prospectus supplement ("Prospectus Supplement"), in the accompanying prospectus and in the statement of additional information ("SAI").*

---

| | |
|:---|:---|
| **The Fund** | Nuveen Real Asset Income and Growth Fund (the "Fund") is a diversified, closed-end management investment company. The Fund's common shares, $0.01 par value per share (the "Common Shares"), are traded on the NYSE under the symbol "JRI." See "Description of Shares—Common Shares" in the accompanying prospectus. |
| **Investment Adviser** | Nuveen Fund Advisors, LLC ("Nuveen Fund Advisors") is the Fund's investment adviser, responsible for overseeing the Fund's overall investment strategy and its implementation. |
|  | Nuveen Fund Advisors, a registered investment adviser, offers advisory and investment management services to a broad range of investment company clients. Nuveen Fund Advisors has overall responsibility for management of the Fund, oversees the management of the Fund's portfolio, manages the Fund's business affairs and provides certain clerical, bookkeeping and other administrative services. Nuveen Fund Advisors is located at 333 West Wacker Drive, Chicago, Illinois 60606. Nuveen Fund Advisors is an indirect subsidiary of Nuveen, LLC ("Nuveen"), the investment management arm of Teachers Insurance and Annuity Association of America ("TIAA"). TIAA is a life insurance company founded in 1918 by the Carnegie Foundation for the Advancement of Teaching and is the companion organization of College Retirement Equities Fund. As of December 31, 2025, Nuveen managed approximately $1.4 trillion in assets, of which approximately $157.4 billion was managed by Nuveen Fund Advisors. |
| **Sub-Adviser** | Nuveen Asset Management, LLC ("Nuveen Asset Management"), located at 333 West Wacker Drive, Chicago, Illinois 60606, serves as the Fund's investment sub-adviser and is an affiliate of Nuveen Fund Advisors. Nuveen Asset Management is a registered investment adviser. Nuveen Asset Management oversees the day-to-day investment operations of the Fund. |
| **Purpose of the Rights Offering** | The Board of Trustees of the Fund (the "Board"), based on the recommendations and presentations of Nuveen Fund Advisors, has determined that it is in the best interests of the Fund and holders of its Common Shares (the "Common Shareholders") to conduct this offering of transferable subscription rights ("Rights," and each, a "Right"), thereby increasing the assets of the Fund available for investment. |
|  | Nuveen Fund Advisors believes that a variety of factors indicate that there may be opportunities to make new, attractive investments. Nuveen Fund Advisors expects that the Rights offering will provide an opportunity to increase the assets of the Fund available for investment, thereby better enabling the Fund to take advantage more fully of existing and future investment opportunities that may be or may become available, consistent with the Fund's investment objective to achieve a high level of current income and long-term capital appreciation. Nuveen Fund Advisors believes that the Fund may benefit from increased yields, enhanced earnings, tax efficiency and lower expenses.  |

---

---

| | |
|:---|:---|
| **Terms of the Rights Offering** | One Right will be issued for each Common Share held on the Record Date (as defined below). Rights are expected to trade on the New York Stock Exchange (the "NYSE") under the symbol "JRI RT." The Rights will allow Common Shareholders to subscribe for new Common Shares of the Fund. Four Rights will be required to purchase one Common Share (1 for 4). Upon exercise of the Rights offering, Common Shares may be issued at a price below net asset value ("NAV") per Common Share. 27,448,277 Common Shares of the Fund are outstanding as of January 21, 2026. If all Rights in the Primary Subscription are exercised, up to 7,000,000 Common Shares of the Fund could be issued. The actual number of Common Shares issued will be based upon the total number of Common Shares outstanding as of the Record Date, which will be impacted by certain events, such as the issuance of new Common Shares pursuant to the Fund's dividend reinvestment plan. See "Description of the Rights Offering—Terms of the Rights Offering." Fractional shares will not be issued upon exercise of Rights. Accordingly, Common Shares may be purchased only pursuant to the exercise of Rights in integral multiples of four. The number of Rights issued to a Record Date Shareholder will be rounded up to the nearest number of Rights evenly divisible by four.<br>An over-subscription privilege will be offered to Record Date Shareholders who fully exercise all Rights initially issued to them to buy those Common Shares that were not purchased by other Rights holders at the same Subscription Price (as defined below), subject to the right of the Board to eliminate the over-subscription privilege (the "Primary Over-Subscription Privilege"). Common Shares issued pursuant to the Primary Over-Subscription Privilege are referred to as "Primary Over-Subscription Shares." Further, if the number of Common Shares requested by Record Date Shareholders exceeds the amount of Common Shares available in the Primary Subscription, the Fund may, subject to the approval of the Board, determine to issue additional Common Shares in an amount of up to 25% of the number of Common Shares issued pursuant to the Primary Subscription (the "Secondary Over-Subscription Privilege"). This amounts to up to an additional 1,750,000 Common Shares, for an aggregate total of up to 8,750,000 Common Shares. Common Shares issued pursuant to the Secondary Over-Subscription Privilege are referred to as the "Secondary Over-Subscription Shares," and together with the Primary Over-Subscription Shares are referred to as the "Over-Subscription Shares." Should the Fund determine to issue any Secondary Over-Subscription Shares, such Secondary Over-Subscription Shares will be allocated only among Record Date Shareholders who submitted requests for Over-Subscription Shares on their Subscription Certificate (as defined below). Over-Subscription Shares will be allocated pro rata among those fully exercising Record Date Shareholders who over-subscribe based on the number of Rights originally issued to them by the Fund.  |
|  | The Fund has declared monthly distributions payable on March 2, 2026 and April 1, 2026, with record dates of February 13, 2026 and March 2, 2026, respectively. ***Any Common Shares issued after such record dates as a result of the Rights offering will not be record date Common Shares for the Fund's monthly distributions to be paid on March 2, 2026 and April 1, 2026 and will not be entitled to receive such distributions.*** |
|  | Rights may be evidenced by subscription certificates or may be uncertificated and evidenced by other appropriate documentation (i.e., a rights card distributed to registered shareholders in lieu of a subscription certificate) (each, a "Subscription Certificate"). |
|  | **The exercise of Rights by a Rights holder is irrevocable.** |

---

---

| | |
|:---|:---|
| **Subscription Price** | The subscription price per Common Share (the "Subscription Price") will be determined based upon a formula equal to 95% of the average of the last reported sales price of the Common Shares on the NYSE on the Expiration Date (as defined below) and each of the four (4) preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 90% of the NAV per Common Share at the close of trading on the NYSE on the Expiration Date, then the Subscription Price will be 90% of the Fund's NAV per Common Share at the close of trading on the NYSE on the Expiration Date. The Rights offering will expire at 5:00 p.m., Eastern Time, on March 9, 2026 (the "Expiration Date").<br>|
| **Record Date** | Rights will be issued to Common Shareholders of record as of the close of business on February 6, 2026 (the "Record Date"). See "Description of the Rights Offering—Terms of the Rights Offering."<br>|
| **Primary and Secondary<br> Over-Subscription Privilege** | Common Shareholders as of the close of business on the Record Date who fully exercise all Rights initially issued to them are entitled to buy Primary Over-Subscription Shares. If enough Primary Over-Subscription Shares are available, all such requests will be honored in full. If the requests for Primary Over-Subscription Shares exceed the Primary Over-Subscription Shares available, the available Primary Over-Subscription Shares will be allocated pro rata among those fully exercising Record Date Shareholders who over-subscribe based on the number of Rights originally issued to them by the Fund. Common Shares acquired pursuant to the Primary Over-Subscription Privilege are subject to allotment. ***Rights acquired in the secondary market may not participate in the Primary Over-Subscription Privilege****.*<br>Further, if the number of Common Shares requested by Record Date Shareholders exceeds the amount of Common Shares available in the Primary Subscription, the Fund may, subject to the approval of the Board, elect to issue up to an additional 25% of the amount of Common Shares offered in the Primary Subscription through a Secondary Over-Subscription Privilege. The Secondary Over-Subscription Shares will be allocated only among Record Date Shareholders who requested Over-Subscription Shares as part of the Primary Subscription. To the extent a sufficient amount of Common Shares are not available to fulfill all over-subscription requests, Common Shares will be allocated pro rata among those Record Date Shareholders who over-subscribe based on the number of Rights originally issued to them by the Fund. Like Primary Over-Subscription Shares, Secondary Over-Subscription Shares are subject to allotment. ***Rights acquired in the secondary market may not participate in the Secondary Over-Subscription Privilege.***<br>Notwithstanding the above, the Board has the right in its absolute discretion to eliminate the Primary Over-Subscription Privilege if it considers it to be in the best interest of the Fund to do so. The Board may make that determination at any time, without prior notice to Rights holders or others, up to and including the fifth day following the Expiration Date. See "Description of the Rights Offering—Primary and Secondary Over-Subscription Privilege."<br>Common Shareholders who choose not to exercise their full Rights to purchase additional Common Shares will permit Common Shareholders who exercise an over-subscription privilege to purchase additional Common Shares at a discount to NAV without furnishing additional Rights or providing any compensation to the non-participating Common Shareholders for the dilution of their ownership percentage or voting rights.<br>Any Common Shares issued pursuant to an over-subscription privilege will be shares registered under the Prospectus.  |

---

---

| | |
|:---|:---|
| **Transfer of Rights** | The Rights will be transferable. See "Description of the Rights Offering—Terms of the Rights Offering," "Sale of Rights" and "Method of Transferring Rights."<br>|
| **Title** | Subscription Rights to Acquire Common Shares.<br>|
| **Subscription Period** | The Rights may be exercised at any time after issuance and prior to expiration of the Rights (the "Subscription Period"), which will be 5:00 p.m., Eastern Time, on March 9, 2026 (the "Expiration Date"), unless otherwise extended. See "Description of the Rights Offering—Terms of the Rights Offering" and "—Method of Exercise of Rights." The Rights offering may be terminated or extended by the Fund at any time for any reason before the Expiration Date. If the Fund terminates the Rights offering, the Fund will issue a press release announcing such termination and will direct the Subscription Agent (defined below) to return, without interest, all subscription proceeds received to such shareholders who had elected to purchase Common Shares.<br>|
| **Offering Expenses** | The expenses of the Rights offering are expected to be approximately $400,000 and will be borne by Nuveen Fund Advisors, and not the Fund or Common Shareholders. See "Use of Proceeds."<br>|
| **Sale of Rights** | The Rights are transferable until the completion of the Subscription Period and will be admitted for trading on the NYSE under the symbol "JRI RT." Although no assurance can be given that a market for the Rights will develop or be maintained, trading in the Rights on the NYSE is expected to begin February 5, 2026, one Business Day prior to the Record Date, and may be conducted until the close of trading on the last NYSE trading day prior to the Expiration Date. For purposes of this Prospectus Supplement, a "Business Day" shall mean any day on which trading is conducted on the NYSE.<br>The value of the Rights, if any, will be reflected by their market price on the NYSE. Rights may be sold by individual holders through their broker or financial advisor or may be submitted to the Subscription Agent (defined below) for sale. Any Rights submitted to the Subscription Agent for sale must be received by the Subscription Agent prior to 5:00 p.m., Eastern Time, on or before March 2, 2026, five Business Days prior to the Expiration Date (or, if the Subscription Period is extended, prior to 5:00 p.m., Eastern Time, on the fifth Business Day prior to the extended Expiration Date).<br>Rights that are sold will not confer any right to acquire any Common Shares in any over-subscription, and any Record Date Shareholder who sells any Rights will not be eligible to participate in the over-subscription privilege, if any.<br>Trading of the Rights on the NYSE will be conducted on a when-issued basis until and including the date on which the Subscription Certificates (as defined below) are mailed to Record Date Shareholders of record and thereafter will be conducted on a regular-way basis until and including the last NYSE trading day prior to the completion of the Subscription Period. The Common Shares are expected to begin trading ex-Rights on the Record Date.<br>If the Subscription Agent receives Rights for sale in a timely manner, the Subscription Agent will use its best efforts to sell the Rights on the NYSE. The Subscription Agent will also attempt to sell any Rights attributable to shareholders of record whose addresses are outside the United States, or who have an APO or FPO address. See "Description of the Rights Offering—Foreign Restrictions." The Subscription Agent will attempt to sell such Rights on the NYSE.  |
|  | Any commissions will be paid by the selling Rights holders. Neither the Fund nor the Subscription Agent will be responsible if Rights cannot be sold and neither has guaranteed any minimum sales price for the Rights. If the Rights can be sold, sales of these Rights will be deemed to have been effected at the weighted average price received by the Subscription Agent on the day such Rights are sold, less any applicable brokerage commissions, taxes and other expenses (i.e., costs incidental to the sale of Rights). |

---

---

| | |
|:---|:---|
|  | Common Shareholders are urged to obtain a recent trading price for the Rights on the NYSE from their broker, bank, financial advisor or the financial press. |
|  | Banks, broker-dealers and trust companies that hold shares for the accounts of others are advised to notify those persons that purchase Rights in the secondary market that such Rights will not participate in any over-subscription privilege. See "Description of the Rights Offering—Terms of the Rights Offering." |
| **Use of Proceeds** | The Fund estimates the net proceeds of the Rights offering to be approximately $90,930,000. This figure is based on the estimated Subscription Price per Common Share of $12.99 (95% of the average of the last reported sales price of the Fund's Common Shares on the NYSE on January 21, 2026 and each of the four (4) preceding trading days) and assumes all new Common Shares offered are sold and that the expenses related to the Rights offering estimated at approximately $400,000 are paid by Nuveen Fund Advisors.<br>The Fund intends to invest the net proceeds from the issuance of Rights hereunder in accordance with the Fund's investment objective and policies as set forth in the accompanying prospectus. The Fund currently anticipates that it will be able to invest substantially all of the net proceeds in investments that meet the Fund's investment objective and policies within approximately three months of the receipt of such proceeds; however, the identification of appropriate investment opportunities pursuant to the Fund's investment style or changes in market conditions may cause the investment period to extend as long as six months (the "invest-up period"). Pending investment, it is anticipated that the proceeds will be invested in short-term or long-term securities issued by the U.S. Government and its agencies or instrumentalities or in high-quality, short-term money market instruments. Current market conditions may change and the Fund may not be able to invest the proceeds as planned. Immediately after the initial invest-up period, the Fund's portfolio allocations may vary over time consistent with the Fund's investment policies as described in the accompanying prospectus.<br>Depending on market conditions and operations, a portion of the cash held by the Fund, including any proceeds raised from the offering, may be used to pay distributions in accordance with the Fund's distribution policy and may be a return of capital. A return of capital is a return to investors of a portion of their original investment in the Fund. In general terms, a return of capital would involve a situation in which a Fund distribution (or a portion thereof) represents a return of a portion of a shareholder's investment in the Fund, rather than making a distribution that is funded from the Fund's earned income or other profits. Although return of capital distributions may not be currently taxable, such distributions would decrease the basis of a shareholder's shares, and therefore, may increase a shareholder's tax liability for capital gains upon a sale of shares, even if sold at a loss to the shareholder's original investments. See "Use of Proceeds."<br>|
| **Taxation/ERISA** | See "Taxation" and "Description of the Rights Offering—Employee Benefit Plan and IRA Considerations."<br>|
| **Subscription Agent** | Computershare Trust Company, N.A. and Computershare Inc. See "Description of the Rights Offering—Subscription Agent."<br>|
| **Information Agent** | Georgeson LLC. See "Description of the Rights Offering—Information Agent." |

---

---

| | |
|:---|:---|
| **Risk Factors** | See "Risk Factors" in the accompanying prospectus and "Special Characteristics and Risks of the Rights Offering" in this Prospectus Supplement for a discussion of the principal risks you should carefully consider before deciding to invest in Common Shares through Rights. |

---

**DESCRIPTION OF THE RIGHTS OFFERING** 

**Purpose of the Rights Offering** 

The Board, based on the recommendations and presentations of Nuveen Fund Advisors, has determined that it is in best interests of the Fund and its Common Shareholders to conduct the Rights offering, thereby increasing the assets of the Fund available for investment. In making this determination, the Board considered a number of factors, including potential benefits and costs. In particular, the Board considered Nuveen Fund Advisors' opinion that the Rights offering would better enable the Fund to take advantage more fully of existing and future investment opportunities that may be or may become available, consistent with the Fund's investment objective.

In making its determination that the Rights offering would result in a net benefit to existing Common Shareholders of the Fund, the Board considered various factors at its meeting held on January 15, 2026, including the advice and recommendations of Nuveen Fund Advisors. The factors considered by the Board included: (i) the size of the Rights offering (including the number of Rights needed to purchase one Common Share and size of the Rights offering in relation to the number of Common Shares outstanding), Subscription Price, pricing (including the pricing formula, as compared to a fixed price, and reasons for selecting the formula) and structure of the Rights offering (including the possible negative effect of the Rights offering on the market price of Common Shares), which will not discriminate among shareholders; (ii) the expected lowering of the Fund's ongoing operating expenses as a proportion of net assets due to the increase in Fund assets as a result of the Rights offering because the Fund's fixed costs would be spread over a larger asset base; (iii) the Rights offering, if it is well-subscribed, which would result in a larger number of outstanding Common Shares and a potentially larger number of beneficial owners of Common Shares, could increase the level of market interest in and visibility of the Fund and improve the trading liquidity of the Common Shares on the NYSE; (iv) the opportunity the Rights offering represents for current Common Shareholders to purchase additional Common Shares at a discount to market price and NAV; (v) Nuveen Fund Advisors' opinion that raising additional capital through a Rights offering would allow the Fund to better capitalize on attractive investment opportunities without having to sell existing positions and that the new investments should be able to help sustain the Fund's current distribution over the longer term; (vi) the size of the current premium to NAV at which the Common Shares are trading and the potential impact of the Rights offering on the market price and premium to NAV of the Common Shares; (vii) the extent of dilution for: (a) participating Common Shareholders, and (b) non-participating Common Shareholders; (viii) the benefits and drawbacks of conducting a non-transferable versus a transferable rights offering and Nuveen Fund Advisors' commitment to use its best efforts to ensure an adequate trading market will exist for the Rights; (ix) the expenses of the Rights offering and Nuveen Fund Advisors' commitment to bear all costs of the Rights offering, which would reduce the effects of any dilution as a result of the Rights offering; and (x) the effect on the Fund and its existing Common Shareholders if the Rights offering is not fully subscribed and, conversely, if the Rights offering is oversubscribed. The Board also considered that increasing the Fund's assets results in a benefit to Nuveen Fund Advisors because the management fee paid by the Fund to Nuveen Fund Advisors increases as the Fund's Managed Assets increase (including from the expected commensurate increase in the Fund's use of leverage).

Nuveen Fund Advisors believes that a variety of factors indicate that there may be opportunities to make new, attractive investments for the Fund. Nuveen Fund Advisors expects that the Rights offering will provide an opportunity to increase the assets of the Fund available for investment. Nuveen Fund Advisors believes that the Fund may benefit from increased yields, enhanced earnings, tax efficiency and lower expenses. Nuveen Fund Advisors has an inherent conflict of interest in recommending the Rights offering because the Fund pays fees to Nuveen Fund Advisors based on a percentage of the Fund's Managed Assets (the greater the Managed Assets of the Fund, the greater the compensation paid to Nuveen Fund Advisors). "Managed Assets" means the total value of the assets of the Fund, minus the sum of its accrued liabilities (other than Fund liabilities incurred for the express purpose of creating leverage). Total assets for this purpose shall include assets attributable to the Fund's use of leverage (whether or not those assets are reflected in the Fund's financial statements for purposes of generally accepted accounting principles).

The Rights offering seeks to provide an opportunity to existing Common Shareholders to purchase Common Shares at a discount to market price and NAV. The issuance to Common Shareholders of transferable Rights, which may themselves have intrinsic value, also will afford non-participating Common Shareholders of record on the Record Date, the potential of receiving cash payment upon the sale of the Rights, receipt of which may be viewed as partial compensation for dilution of their interests that will occur as a result of the Rights offering. There can be no assurance that a market for the Rights will develop or, if such a market does develop, that such market will be maintained or what the price of the Rights will be.

**Terms of the Rights Offering** 

The Fund is issuing to Record Date Shareholders Rights to subscribe for Common Shares of the Fund. Each Record Date Shareholder is being issued one transferable Right for each Common Share owned on the Record Date. The Rights entitle the holder to acquire one new Common Share for every four Rights held (1 for 4) (provided that any Record Date Shareholder who owns fewer than four Common Shares as of the close of business on the Record Date may subscribe for one full Common Share), at a Subscription Price per Common Share determined based upon a formula equal to 95% of the average of the last reported sales price of the Common Shares on the NYSE on the Expiration Date, as such date may be extended from time to time, and each of the four (4) preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 90% of the NAV per Common Share at the close of trading on the NYSE on the Expiration Date, then the Subscription Price will be 90% of the Fund's NAV per Common Share at the close of trading on the NYSE on the Expiration Date.

The estimated Subscription Price to the public of $12.99 is based upon 95% of the average of the last reported sales price of the Common Shares on the NYSE on January 21, 2026 and each of the four (4) preceding trading days. Fractional shares will not be issued upon exercise of Rights. Accordingly, Common Shares may be purchased only pursuant to the exercise of Rights in integral multiples of four. The number of Rights issued to a Record Date Shareholder will be rounded up to the nearest number of Rights evenly divisible by four. Rights may be exercised at any time during the period (the "Subscription Period") which commences on February 6, 2026, and ends at 5:00 p.m., Eastern Time, on March 9, 2026 (the "Expiration Date"), unless otherwise extended. Upon exercise of the Rights offering, Common Shares may be issued at a price below NAV per Common Share. The right to acquire one Common Share for each four Rights held during the Subscription Period (or any extension of the Subscription Period) at the Subscription Price will be referred to in the remainder of this Prospectus Supplement as the "Rights offering." ***Rights will expire on the Expiration Date and all unexercised rights at that time will become void and may not be exercised unless the Expiration Date is extended as described herein.***

The Fund has declared monthly distributions payable on March 2, 2026 and April 1, 2026, with record dates of February 13, 2026 and March 2, 2026, respectively. ***Any Common Shares issued after such record dates as a result of the Rights offering will not be record date Common Shares for the Fund's monthly distributions to be paid on March 2, 2026 and April 1, 2026 and will not be entitled to receive such distributions.***

Rights may be evidenced by subscription certificates or may be uncertificated and evidenced by other appropriate documentation (*i.e.*, a rights card distributed to registered shareholders in lieu of a subscription certificate) ("Subscription Certificates"). The number of Rights issued to each holder will be stated on the Subscription Certificate delivered to the holder. The method by which Rights may be exercised and Common Shares paid for is set forth below in "Method of Exercise of Rights" and "Payment for Shares." A holder of Rights will have no right to rescind a purchase after Computershare Trust Company, N.A. and Computershare Inc. (together, the "Subscription Agent") has received payment. See "Payment for Shares" below. It is anticipated that the Common Shares issued pursuant to an exercise of Rights will be listed on the NYSE.

Holders of Rights who are Record Date Shareholders are entitled to over-subscribe for additional Common Shares at the same Subscription Price pursuant to the Primary Over-Subscription Privilege, subject to certain limitations, allotment and the right of the Board to eliminate the Primary Over-Subscription Privilege.

In addition, if the number of Common Shares requested by Record Date Shareholders exceeds the amount of Common Shares available in the Primary Subscription, the Fund may, subject to the approval of the Board, elect to issue additional Common Shares in an amount of up to 25% of the number of Common Shares issued as part of the Primary Subscription. Should the Fund determine to issue some or all of the Secondary Over-Subscription Shares, they will be allocated only among Record Date Shareholders who requested Over-Subscription Shares on their Subscription Certificate. Secondary Over-Subscription Shares will be allocated pro rata among those fully exercising Record Date Shareholders who over-subscribe based on the number of Rights originally issued to them by the Fund.

The entitlement to subscribe for any Over-Subscription Shares is available only to those Record Date Shareholders who fully exercise all Rights initially issued to them and only on the basis of their Record Date holdings. See below under "Description of the Rights Offering—Primary and Secondary Over-Subscription Privileges" below.

For purposes of determining the maximum number of Common Shares that may be acquired pursuant to the Rights offering, broker-dealers, trust companies, banks or others whose shares are held of record by Cede & Co. ("Cede"), as nominee for the Depository Trust Company ("DTC"), or by any other depository or nominee will be deemed to be the holders of the Rights that are held by Cede or such other depository or nominee on their behalf.

The Rights are transferable until the completion of the Subscription Period and will be admitted for trading on the NYSE under the symbol "JRI RT." Assuming a market exists for the Rights, the Rights may be purchased and sold through usual brokerage channels and also sold through the Subscription Agent. Although no assurance can be given that a market for the Rights will develop or be maintained, trading in the Rights on the NYSE is expected to begin February 5, 2026, one Business Day prior to the Record Date, and may be conducted until the close of trading on the last NYSE trading day prior to the Expiration Date. Trading of the Rights on the NYSE is expected to be conducted on a when-issued basis on February 5, 2026 until and including the date on which the Subscription Certificates are mailed to Record Date Shareholders of record and thereafter is expected to be conducted on a regular way basis until and including the last NYSE trading day prior to the Expiration Date. The method by which Rights may be transferred is set forth below under "Method of Transferring Rights." The Common Shares are expected to begin trading ex-Rights on the Record Date as determined and announced by the NYSE. The Rights offering may be terminated or extended by the Fund at any time for any reason before the Expiration Date. If the Fund terminates the Rights offering, the Fund will issue a press release announcing such termination and will direct the Subscription Agent to return, without interest, all subscription proceeds received to such shareholders who had elected to purchase Common Shares.

Nominees who hold Common Shares for the account of others, such as banks, broker-dealers, trustees or depositories for securities, should notify the respective beneficial owners of such shares as soon as possible to ascertain such beneficial owners' intentions and to obtain instructions with respect to the Rights. If the beneficial owner so instructs, the nominee should complete the Subscription Certificate and submit it to the Subscription Agent with proper payment. In addition, beneficial owners of the Common Shares or Rights held through such a nominee should contact the nominee and request the nominee to effect transactions in accordance with such beneficial owner's instructions.

Participants in the Fund's Dividend Reinvestment Plan (the "Plan") will be issued Rights in respect of the Common Shares held in their accounts in the Plan. Participants wishing to exercise these Rights must exercise the Rights in accordance with the procedures set forth in "Method of Exercise of Rights" and "Payment for Shares."

**Conditions of the Rights Offering** 

The Rights offering is being made in accordance with the Investment Company Act of 1940, as amended (the "1940 Act"), without shareholder approval. The staff of the SEC has interpreted the 1940 Act as not requiring shareholder approval of a transferable rights offering to purchase common shares at a price below the then current NAV so long as certain conditions are met, including: (i) the Board make a good faith determination that such offering would result in a net benefit to existing shareholders; (ii) the offering fully protects shareholders' preemptive rights and does not discriminate among shareholders (except for the possible effect of not offering fractional rights); (iii) management uses its best efforts to ensure an adequate trading market in the Rights for use by shareholders who do not exercise such Rights; and (iv) the ratio of such transferable Rights offering does not exceed one new share for each three rights held.

**Important Dates to Remember** 

Please note that the dates in the table below may change if the Rights offering is extended.

---

| | |
|:---|:---|
| **Event** | **Date** |
| Record Date | February 6, 2026 |
| Subscription Period | February 6, 2026 through March 9, 2026† |
| Final Day Rights Will Trade | March 6, 2026† |
| Expiration Date\* | March 9, 2026† |
| Notice of Guaranteed Delivery Due\* | March 9, 2026† |
| Guarantee Expiration Date | March 10, 2026† |
| Issuance Date | March 16, 2026† |
| Confirmation Date | March 19, 2026† |

---

\* A shareholder exercising Rights must deliver to the Subscription Agent by 5:00 p.m., Eastern Time, on March 9, 2026 (unless the Rights offering is extended) either (a) a Subscription Certificate and payment for Common Shares or (b) a notice of guaranteed delivery and payment for Common Shares.

† Unless the Rights offering is extended.

**Primary and Secondary Over-Subscription Privilege**

Record Date Shareholders who fully exercise their Rights are entitled to subscribe for additional Common Shares at the same Subscription Price pursuant to the Primary and Secondary Over-Subscription Privilege, subject to certain limitations and subject to allotment. The Board has the right in its absolute discretion to eliminate the Primary Over-Subscription Privilege if it considers it to be in the best interest of the Fund to do so. The Board may make that determination at any time, without prior notice to Rights holders or others, up to and including the fifth day following the Expiration Date. If the Primary Over-Subscription Privilege is exercised, it will operate as set forth below.

Record Date Shareholders who fully exercise all Rights initially issued to them are entitled to buy those Common Shares, referred to as Primary Over-Subscription Shares, that were not purchased by other holders of Rights at the same Subscription Price. If enough Primary Over-Subscription Shares are available, all such requests will be honored in full. Common Shares acquired pursuant to the Primary Over-Subscription Privilege are subject to allotment.

If the number of Common Shares requested by Record Date Shareholders exceeds the amount of Common Shares available in the Primary Subscription, the Fund may, subject to the approval of the Board, elect to issue Secondary Over-Subscription Shares in an amount of up to 25% of the number of Common Shares issued pursuant to the Primary Subscription. Should the Fund determine to issue some or all of the Secondary Over-Subscription Shares, they will be allocated only among Record Date Shareholders who requested Over-Subscription Shares on their Subscription Certificate. Common Shares acquired pursuant to the Secondary Over-Subscription Privilege are subject to allotment.

Record Date Shareholders who are fully exercising their Rights during the Subscription Period should indicate on the Subscription Certificate that they submit with respect to the exercise of the Rights issued to them, how many Common Shares they are willing to acquire pursuant to any Primary Over-Subscription Privilege and Secondary Over-Subscription Privilege. ***Rights acquired in the secondary market may not participate in any Primary Over-Subscription Privilege or Secondary Over-Subscription Privilege.***

To the extent sufficient Common Shares are not available to fulfill all over-subscription requests, the Over-Subscription Shares will be allocated pro rata among those Record Date Shareholders who over-subscribe based on the number of Rights issued to them by the Fund. The allocation process may involve a series of allocations in order to assure that the total number of Common Shares available for over-subscriptions is distributed on a pro rata basis.

The formula to be used in allocating the Over-Subscription Shares is as follows:

---

| | | |
|:---|:---|:---|
| Shareholder's Record Date Position | <br> X | Over-Subscription |
| Total Record Date Position of All Over-Subscribers | <br> X | Shares Remaining |

---

Banks, broker-dealers, trustees and other nominee holders of Rights will be required to certify to the Subscription Agent, before any over-subscription privilege may be exercised with respect to any particular beneficial owner, as to the aggregate number of Rights exercised during the Subscription Period and the number of Common Shares subscribed for pursuant to the over-subscription privilege by such beneficial owner and that such beneficial owner's subscription was exercised in full. Nominee holder over-subscription forms and beneficial owner certification forms will be distributed to banks, broker-dealers, trustees and other nominee holders of Rights with the Subscription Certificates. Nominees should also notify holders purchasing Rights in the secondary market that such Rights may not participate in any over-subscription privilege.

Common Shareholders who choose not to exercise their full rights to purchase additional Common Shares will permit Common Shareholders who exercise an over-subscription privilege to purchase additional Common Shares at a discount to NAV without furnishing additional Rights or providing any compensation to the non-participating Common Shareholders for the dilution of their ownership percentage or voting rights.

The Fund will not otherwise offer or sell any Common Shares that are not subscribed for pursuant to the Primary Subscription or over-subscription privileges pursuant to the Rights offering.

**Sale of Rights** 

The Rights are transferable and will be admitted for trading on the NYSE under the symbol "JRI RT." Although no assurance can be given that a market for the Rights will develop or be maintained, trading in the Rights on the NYSE is expected to begin February 5, 2026, one Business Day prior to the Record Date, and may be conducted until the close of trading on the last NYSE trading day prior to the Expiration Date.

The value of the Rights, if any, will be reflected by the market price. Rights may be sold by individual holders through their broker or other financial intermediary. Holders of Rights attempting to sell any unexercised Rights in the open market through their broker or financial advisor may be charged a commission or incur other transaction expenses and should consider the commissions and fees charged prior to selling their Rights on the open market.

Rights that are sold will not confer any right to acquire any Common Shares in any Primary or Secondary Over-Subscription Privilege, if any, and any Record Date Shareholder who sells any Rights will not be eligible to participate in any Primary or Secondary Over-Subscription Privilege.

Trading of the Rights on the NYSE will be conducted on a when-issued basis until and including the date on which the Subscription Certificates are mailed to Record Date Shareholders of record and thereafter will be conducted on a regular-way basis until and including the last NYSE trading day prior to the Expiration Date. The Common Shares are expected to begin trading ex-Rights on the Record Date.

Shareholders are urged to obtain a recent trading price for the Rights on the NYSE from their broker, bank, financial advisor or the financial press.

Holders of Rights who are unable or do not wish to exercise any or all of their Rights may contact the Information Agent if they have questions about the sale of any unexercised Rights. Rights holders who hold their shares through a broker-dealer or other applicable financial intermediary should contact their broker-dealer or other applicable financial intermediary if they wish to sell their Rights. Shareholders of record whose addresses are outside the United States, or who have an APO or FPO address, are encouraged to contact the Information Agent if they want to exercise their Rights. If an instruction to exercise their Rights is not received within five business days of the Expiration Date, their Rights will be sold. The selling Rights holder will pay all applicable brokerage commissions incurred. There can be no assurance that the Subscription Agent will be able to facilitate the sale of any of Rights and neither the Fund nor the Subscription Agent has guaranteed any minimum sales price for the Rights.

**Method of Transferring Rights** 

The Rights evidenced by a single Subscription Certificate may be transferred in whole by endorsing the Subscription Certificate for transfer in accordance with the accompanying instructions. A portion of the Rights evidenced by a single Subscription Certificate (but not fractional Rights) may be transferred by delivering to the Subscription Agent a Subscription Certificate properly endorsed for transfer, with instructions to register the portion of the Rights evidenced thereby in the name of the transferee (and to issue a new Subscription Certificate to the transferee evidencing the transferred Rights). In this event, a new Subscription Certificate evidencing the balance of the Rights will be issued to the Rights holder or, if the Rights holder so instructs, to an additional transferee.

Holders wishing to transfer all or a portion of their Rights (but not fractional Rights) should promptly transfer such Rights to ensure that: (i) the transfer instructions will be received and processed by the Subscription Agent, (ii) a new Subscription Certificate will be issued and transmitted to the transferee or transferees with respect to transferred Rights, and to the holder with respect to retained Rights, if any, and (iii) the Rights evidenced by the new Subscription Certificates may be exercised or sold by the recipients thereof prior to the Expiration Date. Neither the Fund nor the Subscription Agent shall have any liability to a transferee or holder of Rights if Subscription Certificates are not received in time for exercise or sale prior to the Expiration Date.

Except for the fees charged by the Subscription Agent (which will be paid by Nuveen Fund Advisors as described below), all commissions, fees and other expenses (including brokerage commissions and transfer taxes) incurred in connection with the purchase, sale, transfer or exercise of Rights will be for the account of the holder of the Rights, and none of these commissions, fees or expenses will be borne by the Fund or the Subscription Agent.

The Fund anticipates that the Rights will be eligible for transfer through, and that the exercise of the Rights may be effected through, the facilities of DTC (Rights exercised through DTC are referred to as "DTC Exercised Rights").

**Subscription Agent**

The Subscription Agent is Computershare Trust Company, N.A. and Computershare Inc. The Subscription Agent will receive an amount estimated to be $70,000, comprised of the fee for its services and the reimbursement for certain expenses related to the Rights offering. Nuveen Fund Advisors, not the Fund or Common Shareholders, will pay such amount.

**Information Agent**

INQUIRIES BY ALL HOLDERS OF RIGHTS SHOULD BE DIRECTED TO: THE INFORMATION AGENT, GEORGESON LLC. BANKS, BROKERS AND SHAREHOLDERS PLEASE CALL TOLL-FREE AT 866-946-4206.

**Method of Exercise of Rights** 

Rights may be exercised by completing and signing the Subscription Certificate and delivering the completed and signed Subscription Certificate to the Subscription Agent, together with payment for the Common Shares as described below under "Payment for Shares." Rights may also be exercised through the broker of a holder of Rights, who may charge the holder of Rights a servicing fee in connection with such exercise.

Completed Subscription Certificates and payment must be received by the Subscription Agent prior to 5:00 p.m., Eastern Time, on the Expiration Date (unless payment is effected by means of a notice of guaranteed delivery as described below under "Payment for Shares"). Your broker, bank, trust company or other intermediary may impose a deadline for exercising Rights earlier than 5:00 p.m., Eastern Time, on the Expiration Date. The Subscription Certificate and payment should be delivered to the Subscription Agent at the following address:

If By Mail:

Computershare

C/O Voluntary Corporate Actions

P.O. Box 43011

Providence, RI 02940-3011

If By Overnight Courier:

Computershare

C/O Voluntary Corporate Actions

150 Royall Street, Suite V

Canton, MA 02021

If By Notice of Guaranteed Delivery:

email to canoticeofguarantee@computershare.com

Contact your broker-dealer, trust company, bank or other nominee to notify the Fund of your intent to exercise, sell or transfer the Rights.

**Payment for Shares** 

Holders of Rights who acquire Common Shares in the Rights offering may choose between the following methods of payment:

&nbsp;&nbsp;&nbsp;&nbsp;(1) A holder of Rights can send the Subscription Certificate, together with payment in the form
 of a check (which must include the name of the shareholder on the check) for the Common Shares subscribed for in the Rights offering
 and, if eligible, for any additional Common Shares subscribed for pursuant to the over-subscription privilege, to the Subscription
 Agent based on the estimated Subscription Price. To be accepted, the payment, together with the executed Subscription Certificate,
 must be received by the Subscription Agent at one of the addresses noted above prior to 5:00 p.m., Eastern Time, on the Expiration
 Date. The Subscription Agent will deposit all share purchase checks received by it prior to the final due date into a segregated
 account pending proration and distribution of Common Shares. The Subscription Agent will not accept cash as a means of payment for
 Common Shares.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Alternatively, a subscription will be accepted by the Subscription Agent if, prior to 5:00
 p.m., Eastern Time, on the Expiration Date, the Subscription Agent has received a written notice of guaranteed delivery by mail or
 email from a bank, trust company, or a NYSE member, guaranteeing delivery of a properly completed and executed Subscription Certificate.
 In order for the notice of guarantee to be valid, full payment for the Common Shares at the estimated Subscription Price must be
 received with the notice. The Subscription Agent will not honor a notice of guaranteed delivery unless a properly completed and executed
 Subscription Certificate is received by the Subscription Agent by the close of business on the first Business Day after the Expiration
 Date. The notice of guaranteed delivery must be emailed to the Subscription Agent at canoticeofguarantee@computershare.com or delivered
 to the Subscription Agent at one of the addresses noted above.

**A PAYMENT PURSUANT TO THIS METHOD MUST BE IN UNITED STATES DOLLARS BY CHECK (WHICH MUST INCLUDE THE NAME OF THE SHAREHOLDER ON THE CHECK) DRAWN ON A BANK LOCATED IN THE UNITED STATES, MUST BE PAYABLE TO NUVEEN REAL ASSET INCOME AND GROWTH FUND AND MUST ACCOMPANY AN EXECUTED SUBSCRIPTION CERTIFICATE TO BE ACCEPTED.**

If a holder of Rights who acquires Common Shares pursuant to the subscription makes payment of an insufficient amount, the Fund reserves the right to take any or all of the following actions: (i) reallocate such subscribed and unpaid-for Common Shares to Record Date Shareholders exercising the over-subscription privilege who did not receive the full over-subscription requested; (ii) apply any payment actually received by it toward the purchase of the greatest whole number of Common Shares which could be acquired by such holder upon exercise of the Rights or any over-subscription privilege; and (iii) exercise any and all other rights or remedies to which it may be entitled, including, without limitation, the right to set off against payments actually received by it with respect to such subscribed Common Shares (in other words, retain such payments) and to enforce the exercising Rights holder's relevant payment obligation.

Any payment required from a holder of Rights must be received by the Subscription Agent prior to 5:00 p.m., Eastern Time, on the Expiration Date. Issuance and delivery of the Common Shares purchased are subject to collection of checks.

Within eight Business Days following the Expiration Date (the "Confirmation Date"), a confirmation will be sent by the Subscription Agent to each holder of Rights (or, if the Common Shares are held by Cede or any other depository or nominee, to Cede or such other depository or nominee), showing (i) the number of Common Shares acquired pursuant to the Primary Subscription, (ii) the number of Over-Subscription Shares, if any, acquired pursuant to any over-subscription privilege, and (iii) the per share and total purchase price for the Common Shares. Any additional payment required from a Record Date Shareholder for the difference between the estimated Subscription Price and the actual Subscription Price will be reflected in an invoice to such shareholder. Any excess payment to be refunded by the Fund to a holder of Rights, or to be paid to a holder of Rights as a result of sales of Rights on its behalf by the Subscription Agent, will be mailed by the Subscription Agent to the holder within eight Business Days after the Expiration Date.

A holder of Rights will have no right to rescind a purchase after the Subscription Agent has received payment either by means of a notice of guaranteed delivery or a check, which must include the name of the shareholder on the check.

Upon acceptance of a subscription, all funds received by the Subscription Agent shall be held by the Subscription Agent as agent for the Fund and deposited in one or more bank accounts. Such funds may be invested by the Subscription Agent in bank accounts, short-term certificates of deposit, bank repurchase agreements, and disbursement accounts with commercial banks meeting certain standards. The Subscription Agent may receive interest, dividends or other earnings in connection with such deposits or investments.

Holders, such as broker-dealers, trustees or depositories for securities, who hold Common Shares for the account of others, should notify the respective beneficial owners of the Common Shares as soon as possible to ascertain such beneficial owners' intentions and to obtain instructions with respect to the Rights. If the beneficial owner so instructs, the record holder of the Rights should complete Subscription Certificates and submit them to the Subscription Agent with the proper payment. In addition, beneficial owners of Common Shares or Rights held through such a holder should contact the holder and request that the holder effect transactions in accordance with the beneficial owner's instructions. **Banks, broker-dealers, trustees and other nominee holders that hold Common Shares of the Fund for the accounts of others are advised to notify those persons that purchase Rights in the secondary market that such Rights may not participate in any over-subscription privilege offered.**

**THE INSTRUCTIONS ACCOMPANYING THE SUBSCRIPTION CERTIFICATES SHOULD BE READ CAREFULLY AND FOLLOWED IN DETAIL. DO NOT SEND SUBSCRIPTION CERTIFICATES TO THE FUND.** 

**THE METHOD OF DELIVERY OF SUBSCRIPTION CERTIFICATES AND PAYMENT OF THE ESTIMATED SUBSCRIPTION PRICE TO THE SUBSCRIPTION AGENT WILL BE AT THE ELECTION AND RISK OF THE RIGHTS HOLDERS, BUT IF SENT BY MAIL IT IS RECOMMENDED THAT THE CERTIFICATES AND PAYMENTS BE SENT BY REGISTERED MAIL, PROPERLY INSURED, WITH RETURN RECEIPT REQUESTED, AND THAT A SUFFICIENT NUMBER OF DAYS BE ALLOWED TO ENSURE DELIVERY TO THE SUBSCRIPTION AGENT AND CLEARANCE OF PAYMENT PRIOR TO 5:00 P.M., EASTERN TIME, ON THE EXPIRATION DATE BECAUSE UNCERTIFIED PERSONAL CHECKS MAY TAKE AT LEAST FIVE BUSINESS DAYS TO CLEAR.** 

All questions concerning the timeliness, validity, form and eligibility of any exercise of Rights will be determined by the Fund, whose determinations will be final and binding. The Fund in its sole discretion may waive any defect or irregularity, or permit a defect or irregularity to be corrected within such time as it may determine, or reject the purported exercise of any Right. Subscriptions will not be deemed to have been received or accepted until all irregularities have been waived or cured within such time as the Fund determines in its sole discretion. Neither the Fund nor the Subscription Agent will be under any duty to give notification of any defect or irregularity in connection with the submission of Subscription Certificates or incur any liability for failure to give such notification.

**Foreign Restrictions**

Subscription Certificates will only be mailed to Record Date Shareholders whose addresses are within the United States (other than an APO or FPO address). Because the Rights offering will not be registered in any jurisdiction other than the United States, shareholders of record in any jurisdiction outside of the United States should contact the Information Agent for assistance in facilitating the sale of the Rights issued to Record Date Shareholders outside of the United States. The Subscription Agent will attempt to sell all of the Rights issued to shareholders outside these jurisdictions and remit the net proceeds, if any, to such shareholders of record. If the Rights can be sold, sales of these Rights will be deemed to have been effected at the weighted average price received by the Subscription Agent on the day the Rights are sold, less any applicable brokerage commissions, taxes and other expenses.

For beneficial owners of the Fund's Common Shares who hold their Common Shares through a custodian bank, broker, dealer, or other nominee, it is the responsibility of the nominee holder to determine whether the beneficial owner is eligible to participate in the jurisdiction in which they reside, as the nominee holder will submit instructions on behalf of the beneficial owner through DTC.

**Employee Benefit Plan and IRA Considerations** 

Holders of Rights that are employee benefit plans subject to limitations imposed by the Internal Revenue Code of 1986, as amended (the "Code"), such as employee plans subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), Keogh Plans and Individual Retirement Accounts ("IRA") (each a "Benefit Plan" and collectively, "Benefit Plans"), should be aware that the use of additional contributions of cash outside of the Benefit Plan to exercise Rights may be treated as additional contributions to the Benefit Plan. When taken together with contributions previously made, such deemed additional contributions may be in excess of tax limitations and subject the Rights holder to excise taxes for excess or nondeductible contributions. In the case of Benefit Plans qualified under Section 401(a) of the Code, additional contributions could cause the maximum contribution limitations of Section 415 of the Code or other qualification rules to be violated. Benefit Plans contemplating making additional contributions to exercise Rights should consult with their legal and tax counsel prior to making such contributions.

Benefit Plans and other tax-exempt entities, including governmental plans, should also be aware that if they borrow to finance their exercise of Rights, they may become subject to the tax on unrelated business taxable income ("UBTI") under Section 511 of the Code. If any portion of an IRA is used as security for a loan, the portion so used may also be treated as distributed to the IRA depositor.

A Benefit Plan may also be subject to laws, such as ERISA, that impose certain requirements on the Benefit Plan and on those persons who are fiduciaries with respect to the Benefit Plans. Such requirements may include prudence and diversification requirements and require that investments be made in accordance with the documents governing the Benefit Plan. The exercise of Rights by a fiduciary for a Benefit Plan should be considered in light of such fiduciary requirements.

In addition, ERISA and the Code prohibit certain transactions involving the assets of a Benefit Plan and certain persons (referred to as "parties in interest" for purposes of ERISA and "disqualified persons" for purposes of the Code) having certain relationships to such Benefit Plans, unless a statutory or administrative exemption is applicable to the transaction. A party in interest or disqualified person who engages in a nonexempt prohibited transaction may be subject to excise taxes and other penalties and liabilities under ERISA and the Code (or with respect to certain Benefit Plans, such as IRAs, a prohibited transaction may cause the Benefit Plan to lose its tax-exempt status). In this regard, the U.S. Department of Labor has issued prohibited transaction class exemptions ("PTCEs") that may apply to the exercise of the Rights and holding of the Common Shares. These class exemptions include, without limitation, PTCE 84-14 respecting transactions determined by independent qualified professional asset managers, PTCE 90-1 respecting insurance company pooled separate accounts, PTCE 91-38 respecting bank collective investment funds, PTCE 95-60 respecting life insurance company general accounts and PTCE 96-23 respecting transactions determined by in-house asset managers, PTCE 84-24 governing purchases of shares in investment companies) and PTCE 75-1 respecting sales of securities. In addition, Section 408(b)(17) of ERISA and Section 4975(d)(20) of the Code each provides a limited exemption, commonly referred to as the "service provider exemption," from the prohibited transaction provisions of ERISA and Section 4975 of the Code for certain transactions between a Benefit Plan and a person that is a party in interest and/or a disqualified person (other than a fiduciary or an affiliate that, directly or indirectly, has or exercises any discretionary authority or control or renders any investment advice with respect to the assets of any Benefit Plan involved in the transaction) solely by reason of providing services to the Benefit Plan or by relationship to a service provider, provided that the Benefit Plan receives no less, nor pays no more, than adequate consideration. There can be no assurance that all of the conditions of any such exemptions or any other exemption will be satisfied at the time that the Rights are exercised, or thereafter while the Common Shares are held, if the facts relied upon for utilizing a prohibited transaction exemption change.

Due to the complexity of these rules and the penalties for noncompliance, fiduciaries of Benefit Plans should consult with their legal and tax counsel regarding the consequences of their exercise of Rights under ERISA, the Code and other similar laws.

**SUMMARY OF FUND EXPENSES**

The purpose of the table and the example below is to help you understand all fees and expenses that you, as a shareholder of Common Shares ("Common Shareholder"), would bear directly or indirectly. The table shows the expenses of the Fund as a percentage of the average net assets applicable to Common Shares, and not as a percentage of total assets or Managed Assets.

---

| | |
|:---|:---|
| **Shareholder Transaction Expenses** | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Offering Costs Borne by the Common Shareholders of the Fund (as a percentage of common net assets including proceeds of the offering)<sup>(1)</sup> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Offering Costs (as a percentage of the proceeds of the offering)<sup>(1)</sup> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend Reinvestment Plan Fees<sup>(2)</sup> | $2.50 |

---

---

| | |
|:---|:---|
|  | **As a Percentage <br> of Net Assets<br> Attributable to<br> Common <br> Shares<sup>(3)</sup>** |
| **Annual Expenses** |  |
| Management Fees | 1.42% |
| &nbsp;&nbsp;&nbsp;Interest and Other Related Expenses<sup>(4)</sup> | 2.38% |
| &nbsp;&nbsp;&nbsp;Other Expenses<sup>(5)</sup> | 0.17% |
| Total Annual Expenses | 3.97% |

---

<sup>(1)</sup> Total offering costs, which will be borne by Nuveen Fund Advisors and not the Fund or Common Shareholders, are estimated to be $400,000, which assumes that the Rights offering is fully subscribed.

<sup>(2)</sup> You will be charged a $2.50 service charge and pay brokerage charges if you direct ComputerShare as agent for the Common Shareholders (the "Plan Agent"), to sell your Common Shares held in a dividend reinvestment account.

<sup>(3)</sup> Stated as annualized percentages of average net assets attributable to Common Shares for the six-month period ended June 30, 2025 (unaudited).

<sup>(4)</sup> Interest and Other Related Expenses reflect actual expenses and fees for leverage incurred by the Fund for the six-month period ended June 30, 2025 (annualized). The types of leverage used by the Fund for the six-month period ended June 30, 2025 (annualized) are described in the Fund Leverage and the Notes to Financial Statements sections of the Fund's [semi-annual report](https://www.sec.gov/Archives/edgar/data/1539337/000119312525196804/d64165dncsrs.htm), Actual Interest and Other Related Expenses incurred in the future may be higher or lower. If short-term market interest rates rise in the future, and if the Fund continues to maintain leverage, the cost of which is tied to short-term interest rates, the Fund's interest expenses on its short-term borrowings can be expected to rise in tandem. The Fund's use of leverage will increase the amount of management fees paid to the Fund's adviser and sub-advisor(s).

<sup>(5)</sup> Other Expenses is based on estimated amounts for the current fiscal year. Expenses attributable to the Fund's investments, if any, in other investment companies are currently estimated not to exceed 0.01%. See "The Fund's Investments—Other Investment Companies" in the SAI.

**Example**

The following example illustrates the expenses that a Common Shareholder would pay on a $1,000 investment held for the time periods provided in the table, assuming a 5% annual total return. The example assumes that all dividends and other distributions are reinvested in the Fund and that the Fund's Annual Total Expenses, as provided above, remain the same.<sup>1</sup>

---

| | | | |
|:---|:---|:---|:---|
| **1 Year** | **3 Years** | **5 Years** | **10 Years** |
| $40 | $121 | $204 | $418 |

---

**The example should not be considered a representation of future expenses. Actual expenses may be greater or less than those shown above.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The example assumes that
 all dividends and distributions are reinvested at Common Shares NAV. Actual expenses may be greater or less than those assumed. Moreover,
 the Fund's actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

**TRADING AND NET ASSET VALUE INFORMATION**

The following table shows for the periods indicated: (i) the high and low sales prices for the Common Shares reported as of the end of the day on the NYSE, (ii) the corresponding NAV per share, and (iii) the premium/(discount) to NAV per share at which the Common Shares were trading as of such date. The Fund's Common Shares have historically traded both at premiums and discounts in relation to the Fund's NAV per share. The Fund cannot predict whether its Common Shares will trade at a premium or discount to NAV in the future. The Board of Trustees has currently determined that, at least annually, it will consider action that might be taken to reduce or eliminate any material discount from NAV in respect of Common Shares, which may include the repurchase of such shares in the open market or in private transactions, the making of a tender offer for such shares at NAV, or the conversion of the Fund to an open-end investment company. The Fund cannot assure you that its Board of Trustees will decide to take any of these actions, or that share repurchases or tender offers will actually reduce market discount.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Closing Market<br> Price per** | **Closing Market<br> Price per** | **NAV per Common Share on Date** | **NAV per Common Share on Date** | **Premium/(Discount)<br> on Date of** | **Premium/(Discount)<br> on Date of** |
| | **Common Share** | **Common Share** | **of Market Price** | **of Market Price** | **Market Price** | **Market Price** |
| <br>**Fiscal Quarter Ended** | **High** | **Low** | **High** | **Low** | **High** | **Low** |
| December 2025 | $14.33 | $13.16 | $13.76 | $13.15 | 4.14% | 0.08% |
| September 2025 | $14.25 | $13.03 | $13.71 | $13.38 | 3.94% | (2.62)% |
| June 2025 | $13.50 | $11.26 | $13.56 | $12.32 | (0.44)% | (8.60)% |
| March 2025 | $13.14 | $12.04 | $13.36 | $12.91 | (1.65)% | (6.74)% |
| December 2024 | $13.61 | $11.95 | $14.02 | $12.97 | (2.92)% | (7.86)% |
| September 2024 | $13.67 | $12.21 | $14.54 | $13.21 | (5.98)% | (7.57)% |
| June 2024 | $12.21 | $10.86 | $13.18 | $12.66 | (7.36)% | (14.22)% |
| March 2024 | $12.12 | $11.35 | $13.68 | $13.25 | (11.40)% | (14.34)% |

---

The NAV per Common Share, the market price and percentage of premium/(discount) to NAV per Common Share on January 21, 2026, was $13.57, $13.72, and 1.11%, respectively. As of January 21, 2026, the Fund had 27,448,277 Common Shares outstanding, and net assets applicable to Common Shares of $372,582,069. See "Repurchase of Fund Shares; Conversion to Open-End Fund" in the accompanying prospectus.

**USE OF PROCEEDS**

Assuming the sale of all of the Common Shares offered through Rights under this Prospectus Supplement and the accompanying prospectus, based on the estimated Subscription Price of $12.99 and that the estimated expenses related to the Rights offering of $400,000 are paid by Nuveen Fund Advisors, the Fund estimates the net proceeds of the offering will be approximately $90,930,000. There is no guarantee that there will be any sales of Common Shares through Rights pursuant to this Prospectus Supplement and the accompanying prospectus. Actual sales, if any, of Common Shares through Rights under this Prospectus Supplement and the accompanying prospectus may be less than as set forth above. In addition, the price per share of any such sale may be greater or less than the price set forth above, depending on the market price of Common Shares at the time of any such sale. As a result, the actual net proceeds the Fund receives may be more or less than the amount of net proceeds estimated in this Prospectus Supplement.

The Fund intends to invest the net proceeds from the issuance of Rights hereunder in accordance with the Fund's investment objective and policies as set forth in the accompanying prospectus. The Fund currently anticipates that it will be able to invest substantially all of the net proceeds in investments that meet the Fund's investment objective and policies within approximately three months of the receipt of such proceeds; however, the identification of appropriate investment opportunities pursuant to the Fund's investment style or changes in market conditions may cause the investment period to extend as long as six months (the "invest-up period"). Pending investment, it is anticipated that the proceeds will be invested in short-term or long-term securities issued by the U.S. Government and its agencies or instrumentalities or in high-quality, short-term money market instruments. Current market conditions may change and the Fund may not be able to invest the proceeds as planned. Immediately after the initial invest-up period, the Fund's portfolio allocations may vary over time consistent with the Fund's investment policies as described in the accompanying prospectus.

**CAPITALIZATION**

The Fund is issuing Rights to its Common Shareholders to subscribe for an aggregate of up to 7,000,000 of its Common Shares, $0.01 par value per share. There is no guarantee that there will be any sales of the Common Shares through Rights pursuant to this Prospectus Supplement and the accompanying prospectus.

The following table sets forth the Fund's capitalization (1) on a historical basis as of January 21, 2026 (unaudited); and (2) on a pro forma basis as adjusted to reflect the assumed sale of up to 7,000,000 Common Shares at $12.99 per share (the estimated Subscription Price), through a Rights offering under this Prospectus Supplement and the accompanying prospectus, and assuming that the expenses related to the Rights offering estimated at approximately $400,000 are paid by Nuveen Fund Advisors.

---

| | | |
|:---|:---|:---|
|  | **As of<br> January 21, 2026<br> (unaudited)** | **As Adjusted<br> for Offering<br> (unaudited)** |
| Common shares, $0.01 par value per share | $274483 | $344483 |
| Paid in capital \* | $571848815 | $662708815 |
| Total distributable earnings (loss) | $(199541229) | $(199541229) |
| Net assets applicable to common shares | $372582069 | $463512069 |
| Common shares | 27448277 | 34448277 |
| Net asset value | $13.57 | $13.46 |

---

\* As adjusted Paid in Capital reflects the issuance of up to 7,000,000 Common shares issued in the primary subscription at the estimated Subscription Price of $12.99.

**SPECIAL CHARACTERISTICS AND RISKS OF THE RIGHTS OFFERING**

Risk is inherent in all investing. Therefore, before investing in the Common Shares you should consider the risks associated with such an investment carefully. See "Risk Factors" in the accompanying prospectus. The following summarizes some of the matters that you should consider before investing in Common Shares through the Rights offering:

**Dilution Risk.** Record Date Shareholders who do not fully exercise their Rights will, at the completion of the Rights offering, own a smaller proportional interest in the Fund than owned prior to the Rights offering. The completion of the Rights offering will result in immediate voting dilution for such shareholders. You will also experience an immediate dilution of the aggregate NAV per Common Share if you do not fully participate in the Rights offering. You may also experience a reduction in the NAV per Common Share whether or not you exercise your Rights, as the Subscription Price may be below the Fund's NAV per Common Share on the Expiration Date, because:

● the offered Common Shares may be sold at less than their current NAV; and

● the number of Common Shares outstanding after the Rights offering may have increased proportionately more than the increase in the amount of the Fund's net assets.

The amount of such potential dilution is not currently determinable because it is not known how many Common Shares will be subscribed for, what the NAV per Common Share or market price of the Common Shares will be on the Expiration Date or what the Subscription Price per Common Share will be.

Furthermore, if you do not participate in an over-subscription privilege, if it is available, your percentage ownership may also be diluted. The Fund cannot state precisely the amount of dilution because it is not known at this time what the NAV per Common Share will be on the Expiration Date or what proportion of the Rights will be exercised or what the Subscription Price per Common Share will be. The impact of the Rights offering on NAV per Common Share pursuant to the Primary Subscription is shown by the following example, assuming the Rights offering is fully subscribed and the estimated Subscription Price of $12.99:

---

| | |
|:---|:---|
| **Assumes the Primary Subscription is fully subscribed<sup>(1)</sup>** | **Assumes the Primary Subscription is fully subscribed<sup>(1)</sup>** |
| NAV<sup>(2)</sup> | $13.57 |
| Subscription Price<sup>(3)</sup> | $12.99 |
| Reduction in NAV ($) | $(0.11) |
| Reduction in NAV (%) | (0.81)% |

---

(1) Actual amounts may vary due to rounding.

(2) For illustrative purposes only; reflects the Fund's NAV per Common Share as of January 21, 2026. It is not known
 at this time what the NAV per Common Share will be on the Expiration Date.

(3) For illustrative purposes only; reflects an estimated Subscription Price of $12.99 based upon 95% of the average of the
 last reported sales price of the Common Shares on the NYSE on January 21, 2026, and the four (4) immediately preceding trading
 days. It is not known at this time what the Subscription Price will be on the Expiration Date.

The impact of the Rights offering on NAV per Common Share pursuant to the Primary Subscription and Primary and Secondary Over-Subscription Privileges is shown by the following example that assumes that the Primary Subscription and Primary and Secondary Over-Subscription Privileges are fully subscribed with a $12.99 Subscription Price:

**Assumes full subscription and 25% over-subscription<sup>(1)</sup>**

---

| | |
|:---|:---|
| NAV<sup>(2)</sup> | $13.57 |
| Subscription Price<sup>(3)</sup> | $12.99 |
| Reduction in NAV ($) | $(0.14) |
| Reduction in NAV (%) | (1.03)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Actual amounts may vary due to rounding.

&nbsp;&nbsp;&nbsp;&nbsp;(2) For illustrative purposes only; reflects the Fund's NAV per Common Share as of January
 21, 2026. It is not known at this time what the NAV per Common Share will be on the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;(3) For illustrative purposes only; reflects an estimated Subscription Price of $12.99 based
 upon 95% of the average of the last reported sales price of the Common Share on the NYSE on January 21, 2026, and the four (4)
 immediately preceding trading days. It is not known at this time what the Subscription Price will be on the Expiration Date.

If you do not wish to exercise your Rights, you should consider selling them as set forth in this Prospectus Supplement. Any cash you receive from selling your Rights may serve as partial compensation for dilution of your interest in the Fund. The Fund cannot give assurance, however, that a market for the Rights will develop or be maintained or that the Rights will have any marketable value.

The Fund's largest shareholders could increase their percentage ownership in the Fund through the exercise of the primary subscription and over-subscription privilege.

**Risks of Investing in Rights.** Shares of closed-end funds, such as the Fund, frequently trade at a discount to NAV. Accordingly, the Subscription Price may be greater than the market price of the Common Shares on the Expiration Date. If that is the case, the Rights will have no value, and a person who exercises their Rights will experience an immediate loss of value. Further, because the exercise of Rights is irrevocable, you will not be able to revoke your subscription if the market price of the Common Shares decreases below the Subscription Price prior to delivery of your Common Shares. Moreover, the Fund cannot assure you that you will ever be able to sell the Common Shares that you received in the Rights offering at a price equal to or greater than the Subscription Price.

**No Assurance of Active Trading Market Risk.** Although the Rights are approved for listing on the NYSE, there can be no assurance that an active trading market will develop or be maintained for the Rights. If a trading market is not developed or maintained, you may not be able to transfer your Rights or may have to sell them at an unfavorable price. The transferability of Rights is not guaranteed and investors who do not exercise their Rights prior to the Expiration Date and are unable or unwilling to sell their Rights in the secondary market will realize no value for their Rights.

**Risks of Increases in Share Price Volatility and Decreases in Share Price.** The Rights offering may result in an increase in trading of the Common Shares, which may increase volatility in the market price of the Common Shares. The Rights offering may result in an increase in the number of Common Shareholders wishing to sell their Common Shares, which would exert downward price pressure on the price of Common Shares.

**Risk of Decreased Liquidity Despite Larger Float.** Although the Rights offering will increase the number of Common Shares outstanding, there can be no assurance that the volume of trading in the Common Shares will increase proportionately. As a result, the Rights offering may not materially improve the liquidity of the Common Shares on the secondary market, which could lead to wider bid/ask spreads, increased volatility and greater variances between the market price of the Common Shares and their underlying value.

**Under-Subscription Risk.** It is possible that the Rights offering will not be fully subscribed. Under-subscription of the Rights offering would have an impact on the net proceeds of the Rights offering and whether the Fund achieves any benefits.

**Over-Subscription Risk.** Record Date Shareholders who fully exercise all Rights initially issued to them will be entitled to subscribe for an additional number of Common Shares by exercising their over-subscription privileges. The over-subscription privileges will generally be allocated pro rata among Record Date Shareholders who over-subscribed based on the number of Rights issued to them by the Fund. The Fund cannot guarantee that you will receive any or the entire number of Common Shares for which you over-subscribed. If the pro-rated number of Common Shares allocated to you in connection with your over-subscription privileges is less than your request, then the excess funds held by the Subscription Agent on your behalf will be returned to you, without interest, as soon as practicable after the Rights offering has expired and all pro-rating calculations and reductions contemplated by the terms of the Rights offering have been effected, and the Fund will have no further obligation to you.

**No Assurance or Accretion in NAV or Distributions.** Although the Rights offering will increase the Fund's assets, there can be no assurance that the Rights offering will be accretive to the Fund's NAV per Common Share or its ability to sustain or increase distributions. Investment returns on the proceeds from the Rights offering may be lower than current portfolio returns, and the Fund's distribution rate per Common Share may decline.

**Risk of Delayed Delivery of Common Shares.** If you exercise Rights, you may not be able to resell the Common Shares that you receive in the Rights offering until you, or your custodian bank, broker, dealer or other nominee, if applicable, have received those Common Shares. Moreover, you will have no rights as a shareholder of the Common Shares you received in the Rights offering until the Fund issues those Common Shares to you. Although the Fund will endeavor to issue the Common Shares as soon as practicable after completion of the Rights offering, and after all necessary calculations have been completed, there may be a delay between the Expiration Date and the time that the Common Shares are issued.

**Risk that Market Conditions May Impact Use of Proceeds.** Although the Fund intends to invest the proceeds from the Rights offering as described herein, market or other conditions at the time of investment may result in the Fund making investments with different risk or return characteristics, or at less favorable yields, than currently anticipated, which could adversely affect the Fund's performance and distribution levels.

**Risk of Rejection of Exercise of Rights.** Record Date Shareholders who desire to subscribe for Common Shares in the Rights offering must act promptly to ensure that all required forms and payments are actually received by the Subscription Agent prior to the Expiration Date. If you are a beneficial owner of Common Shares, you must act promptly to ensure that your custodian bank, broker, dealer or other nominee acts for you and that all required forms and payments are actually received by the Subscription Agent prior to the Expiration Date. Your nominee may establish a deadline prior to the Expiration Date by which you must provide it with your instructions to exercise your subscription rights and payment for your Common Shares. The Fund will not be responsible if your custodian bank, broker, dealer or nominee fails to ensure that all required forms and payments are actually received by the Subscription Agent prior to the Expiration Date. If you fail to complete and sign the required Subscription Certificate, send an incorrect payment amount, or otherwise fail to follow the subscription procedures that apply to your desired transaction, the Fund or the Subscription Agent may, depending on the circumstances, reject your subscription or accept it to the extent of the payment received. Neither the Fund nor the Subscription Agent will be under any duty to give notification of any defect or irregularity in connection with the submission of Subscription Certificates or incur any liability for failure to give such notification. The Fund has the sole discretion to determine whether a subscription exercise properly follows the subscription procedures.

**Risk of Termination of Rights Offering.** The Fund reserves the right to terminate, amend or extend the Rights offering at any time for any reason before the Expiration Date. You will not earn any interest on any payment of the Subscription Price you have made while it is being held by the Subscription Agent pending the termination of the Rights offering, even if the Fund amends the terms of the Rights offering to extend the Subscription Period. If the Fund terminates the Rights offering, neither the Fund, the Subscription Agent, your broker, nor any other party will have any obligation to you, except to return any payment of the Subscription Price you have made, which will not accrue interest.

**TAXATION** 

The following is a general summary of the U.S. federal income tax consequences of the Rights offering to Record Date Shareholders who are U.S. persons for U.S. federal income tax purposes. The following summary supplements the discussion set forth in the accompanying prospectus and SAI and is subject to the qualifications and assumptions set forth therein. The discussion set forth herein does not constitute tax advice and potential investors are urged to consult their own tax advisers to determine the tax consequences of investing in the Fund.

Please refer to the "Tax Matters" sections in the accompanying prospectus and SAI for a description of the consequences of investing in the Common Shares. Special tax considerations relating to this Rights offering are summarized below:

● The value of a Right will not be includible in the income of a Common Shareholder at the time the subscription Right is issued.

● The basis of a Right issued to a Common Shareholder will be zero, and the basis of the share with respect to which the Right was issued (the old share) will remain unchanged, unless either (a) the fair market value of the Right on the date of distribution is at least 15% of the fair market value of the old share, or (b) such Common Shareholder affirmatively elects (in the manner set out in Treasury regulations under the Code) to allocate to the Right a portion of the basis of the old share. If either (a) or (b) applies, such Common Shareholder must allocate basis between the old share and the Right in proportion to their fair market values on the date of distribution.

● The basis of a Right purchased in the market will generally be its purchase price.

● The holding period of a Right issued to a Common Shareholder will include the holding period of the old share.

● No loss will be recognized by a Common Shareholder if a Right distributed to such Common Shareholder expires unexercised because the basis of the old share may be allocated to a Right only if the Right is exercised. If a Right that has been purchased in the market expires unexercised, there will be a recognized loss equal to the basis of the Right.

● Any gain or loss on the sale of a Right will be a capital gain or loss if the Right is held as a capital asset (which in the case of a Right issued to Record Date Shareholders will depend on whether the old share is held as a capital asset), and will be a long term capital gain or loss if the holding period is deemed to exceed one year.

● No gain or loss will be recognized by a Common Shareholder upon the exercise of a Right, and the basis of any Common Share acquired upon exercise (the new Common Share) will equal the sum of the basis, if any, of the Right and the subscription price for the new Common Share. The holding period for the new Common Share will begin on the date when the Right is exercised (or, in the case of a Right purchased in the market, potentially the day after the date of exercise).

*The foregoing is a general and abbreviated summary of the provisions of the Code and the Treasury regulations in effect as they directly govern the taxation of the Fund and holders of its Common Shares, with respect to U.S. federal income taxation only. Other tax issues such as state and local taxation may apply. Investors are urged to consult their own tax advisers to determine the tax consequences of investing in the Fund. These provisions are subject to change by legislative or administrative action, and any such change may be retroactive.*

**LEGAL MATTERS**

Certain legal matters in connection with the Common Shares will be passed upon for the Fund by Stradley Ronon Stevens & Young, LLP, located at 2005 Market Street, Suite 2600, Philadelphia, PA 19103. Stradley Ronon Stevens & Young, LLP may rely as to certain matters of Massachusetts law on the opinion of Morgan, Lewis & Bockius LLP.

**AVAILABLE INFORMATION**

The Fund is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the 1940 Act and is required to file reports, proxy statements and other information with the SEC. Reports, proxy statements, and other information about the Fund can be inspected at the offices of the NYSE.

This Prospectus Supplement does not contain all of the information in the Fund's Registration Statement, including amendments, exhibits, and schedules. Additional information about the Fund and the Common Shares can be found in the Fund's Registration Statement (including amendments, sexhibits, and schedules) on Form N-2 filed with the SEC. The SEC maintains a website (www.sec.gov) that contains the Fund's Registration Statement, other documents incorporated by reference, and other information the Fund has filed electronically with the SEC, including proxy statements and reports filed under the Exchange Act.

##### [**Table of Contents**](#toc)
**<u>BASE PROSPECTUS</u>**

![LOGO](nuveenlogo.jpg)

**12,300,000 Shares**

**Common Shares** 

**Preferred Shares** 

**Rights to Purchase Common Shares** 

**Nuveen Real Asset Income and Growth Fund** 

------

***The Offering****.* Nuveen Real Asset Income and Growth Fund (the "Fund") is registering for one or more offerings to be made on an immediate, continuous or delayed basis, up to 12,300,000 common shares ("Common Shares"), preferred shares ("Preferred Shares"), and/or subscription rights to purchase Common Shares ("Rights," and collectively with Common Shares and Preferred Shares, "Securities"), in any combination. The Fund may offer and sell such Securities directly to one or more purchasers, to or through underwriters, through dealers or agents that the Fund designates from time to time, or through a combination of these methods. The prospectus supplement relating to any offering of Securities will describe such offering, including, as applicable, the names of any underwriters, dealers or agents and information regarding any applicable purchase price, fee, commission or discount arrangements made with those underwriters, dealers or agents or the basis upon which such amount may be calculated. The prospectus supplement relating to any Rights offering will set forth the number of Common Shares issuable upon the exercise of each Right (or number of Rights) and the other terms of such Rights offering. For more information about the manners in which the Fund may offer Securities, see "Plan of Distribution."

***The Fund*.** The Fund is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income and long-term capital appreciation. There can be no assurance that the Fund will achieve its investment objective or that the Fund's investment strategies will be successful.

**This Prospectus, together with any related prospectus supplement, sets forth concisely information about the Fund that a prospective investor should know before investing, and should be retained for future reference. Investing in Securities involves risks, including the risks associated with the Fund's use of leverage. You could lose some or all of your investment. You should consider carefully these risks together with all of the other information in this Prospectus and any related prospectus supplement before making a decision to purchase any of the Securities. See "[Risk Factors](#toc780884_9)" beginning on page 14.**

Common Shares are listed on the New York Stock Exchange (the "NYSE"). The trading or "ticker" symbol of the Common Shares is "JRI." The closing price of the Common Shares, as reported by the NYSE on January 13, 2026, was $13.82 per Common Share. The net asset value of the Common Shares at the close of business on that same date was $13.56 per Common Share. Preferred Shares and/or Rights issued by the Fund may also be listed on a securities exchange.

\* \* \*

You should read this Prospectus, together with any related prospectus supplement, which contains important information about the Fund, before deciding whether to invest and retain it for future reference. A [Statement of Additional Information](https://www.sec.gov/Archives/edgar/data/1539337/000199937126001398/jri-n2a_012126.htm), dated January 23, 2026 (the "SAI"), containing additional information about the Fund has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is incorporated by reference in its entirety into this Prospectus. You may request a free copy of the SAI, the table of contents of which is on the last page of this Prospectus, annual and semi-annual reports to shareholders and other information about the Fund and make shareholder inquiries by calling (800) 257-8787, by writing to the Fund at 333 West Wacker Drive, Chicago, Illinois 60606 or from the Fund's website (http://www.nuveen.com). The information contained in, or that can be accessed through, the Fund's website is not part of this Prospectus, except to the extent specifically incorporated by reference herein. You also may obtain a copy of the SAI (and other information regarding the Fund) from the SEC's web site (http://www.sec.gov).

------

The date of this Prospectus is January 23, 2026.

**The Securities do not represent a deposit or obligation of, and are not guaranteed or endorsed by, any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other governmental agency.** 

**Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.** 

##### [**Table of Contents**](#toc)
**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
| [Prospectus Summary](#toc780884_1) | 1 |
| [Summary of Fund Expenses](#toc780884_2) | 7 |
| [Financial Highlights](#toc780884_3) | 8 |
| [Trading and Net Asset Value Information](#toc780884_4) | 9 |
| [The Fund](#toc780884_5) | 9 |
| [Use of Proceeds](#toc780884_6) | 10 |
| [The Fund's Investments](#toc780884_7) | 10 |
| [Use of Leverage](#toc780884_8) | 11 |
| [Risk Factors](#toc780884_9) | 14 |
| [Management of the Fund](#toc780884_10) | 14 |
| [Net Asset Value](#toc780884_11) | 17 |
| [Distributions](#toc780884_12) | 17 |
| [Dividend Reinvestment Plan](#toc780884_13) | 18 |
| [Plan of Distribution](#toc780884_14) | 18 |
| [Description of Shares](#toc780884_15) | 21 |
| [Rights Offerings](#toc780884_16) | 24 |
| [Certain Provisions in the Declaration of Trust and By-Laws](#toc780884_17) | 25 |
| [Repurchase of Fund Shares; Conversion to Open-End Fund](#toc780884_18) | 27 |
| [Tax Matters](#toc780884_19) | 28 |
| [Custodian and Transfer Agent](#toc780884_20) | 29 |
| [Independent Registered Public Accounting Firm](#toc780884_21) | 30 |
| [Legal Matters](#toc780884_22) | 30 |
| [Available Information](#toc780884_23) | 30 |
| [Incorporation By Reference](#toc780884_24) | 30 |

---

------

**You should rely only on the information contained or incorporated by reference into this Prospectus and any related prospectus supplement. The Fund has not authorized anyone to provide you with different information. The Fund is not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information contained in this Prospectus and any related prospectus supplement is accurate as of any date other than the dates on their covers. The Fund will update this Prospectus to reflect any material changes to the disclosures herein.** 

##### [**Table of Contents**](#toc)
**FORWARD-LOOKING STATEMENTS** 

Any projections, forecasts and estimates contained or incorporated by reference herein are forward looking statements and are based upon certain assumptions. Projections, forecasts and estimates are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any projections, forecasts or estimates will not materialize or will vary significantly from actual results. Actual results may vary from any projections, forecasts and estimates and the variations may be material. Some important factors that could cause actual results to differ materially from those in any forward looking statements include changes in interest rates, market, financial or legal uncertainties, including changes in tax law, and the timing and frequency of defaults on underlying investments. Consequently, the inclusion of any projections, forecasts and estimates herein should not be regarded as a representation by the Fund or any of its affiliates or any other person or entity of the results that will actually be achieved by the Fund. Neither the Fund nor its affiliates has any obligation to update or otherwise revise any projections, forecasts and estimates including any revisions to reflect changes in economic conditions or other circumstances arising after the date hereof or to reflect the occurrence of unanticipated events, even if the underlying assumptions do not come to fruition. The Fund acknowledges that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as the Fund.

##### [**Table of Contents**](#toc)
**PROSPECTUS SUMMARY** 

*This is only a summary. You should review the more detailed information contained elsewhere in this Prospectus and any related prospectus supplement and in the Statement of Additional Information (the "SAI").* 

---

| | |
|:---|:---|
| **The Fund**  | Nuveen Real Asset Income and Growth Fund (the "Fund") is a diversified, closed-end management investment company. See "The Fund." The Fund's common shares, $0.01 par value per share ("Common Shares"), are traded on the New York Stock Exchange (the "NYSE") under the symbol "JRI." Preferred Shares and/or Rights issued by the Fund may also be listed on a securities exchange. |

---

The closing price of the Common Shares, as reported by the NYSE on January 13, 2026, was $13.82 per Common Share. The net asset value ("NAV") of the Common Shares at the close of business on that same date was $13.56 per Common Share. As of January 13, 2026, the Fund had 27,448,277 Common Shares outstanding and net assets applicable to Common Shares of $372,305,531. See "Description of Shares."

---

| | |
|:---|:---|
| **The Offering**  | The Fund is registering for one or more offerings up to 12,300,000 Common Shares, preferred shares ("Preferred Shares"), and/or subscription rights to purchase Common Shares ("Rights," and collectively with Common Shares and Preferred Shares, "Securities"), in any combination, on terms to be determined at the time of the offering. The Fund may offer and sell such Securities directly to one or more purchasers, to or through underwriters, through dealers or agents that the Fund designates from time to time, or through a combination of these methods. The prospectus supplement relating to any offering of Securities will describe such offering, including, as applicable, the names of any underwriters, dealers or agents and information regarding any applicable purchase price, fee, commission or discount arrangements made with those underwriters, dealers or agents or the basis upon which such amount may be calculated. For more information about the manners in which the Fund may offer Securities, see "Plan of Distribution." The prospectus supplement relating to any Rights offering will set forth the number of Common Shares issuable upon the exercise of each Right (or number of Rights) and the other terms of such Rights offering. The minimum price on any day at which the Common Shares may be sold will not be less than the NAV per Common Share at the time of the offering plus the per share amount of any underwriting commission or discount; provided that Common Shares offered pursuant to Rights offerings that meet certain conditions may be offered at a price below the then current NAV. See "Rights Offerings." |

---

The Fund may not sell any Securities through agents, underwriters or dealers without delivery, or deemed delivery, of a prospectus, including the appropriate prospectus supplement, describing the method and terms of the particular offering of such Securities. You should read this Prospectus and the applicable prospectus supplement carefully before you invest in our Securities.<br>

##### [**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **Investment Objective and Policies**  | Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Investment Objective" and "—Investment Policies," as such investment objective and investment policies may be supplemented from time to time, which are incorporated by reference herein, for a discussion of the Fund's investment objective and policies. |

---

There can be no assurance that such strategies will be successful. For a more complete discussion of the Fund's portfolio composition and its corresponding risks, see "The Fund's Investments" and "Risk Factors." <br>

---

| | |
|:---|:---|
| **Investment Adviser**  | Nuveen Fund Advisors, LLC ("Nuveen Fund Advisors"), the Fund's investment adviser, is responsible for overseeing the Fund's overall investment strategy and its implementation. Nuveen Fund Advisors offers advisory and investment management services to a broad range of investment company clients. Nuveen Fund Advisors has overall responsibility for management of the Fund, oversees the management of the Fund's portfolio, manages the Fund's business affairs and provides certain clerical, bookkeeping and other administrative services. Nuveen Fund Advisors is located at 333 West Wacker Drive, Chicago, Illinois 60606. Nuveen Fund Advisors is an indirect subsidiary of Nuveen, LLC ("Nuveen"), the investment management arm of Teachers Insurance and Annuity Association of America ("TIAA"). TIAA is a life insurance company founded in 1918 by the Carnegie Foundation for the Advancement of Teaching and is the companion organization of College Retirement Equities Fund. As of December 31, 2025, Nuveen managed approximately $1.4 trillion in assets, of which approximately $157.4 billion was managed by Nuveen Fund Advisors. |

---

---

| | |
|:---|:---|
| **Sub-Adviser** | Nuveen Asset Management, LLC ("Nuveen Asset Management"), located at 333 West Wacker Drive, Chicago, Illinois 60606, serves as the Fund's sub-adviser. Nuveen Asset Management, a registered investment adviser, is a wholly-owned subsidiary of Nuveen Fund Advisors. Nuveen Asset Management oversees the day-to-day investment operations of the Fund. |

---

---

| | |
|:---|:---|
| **Use of Leverage** | The Fund uses leverage to pursue its investment objective. The Fund may source leverage through the issuance of "senior securities" as defined under the Investment Company Act of 1940, as amended (the "1940 Act"), which include (1) borrowings, including loans from financial institutions; (2) the issuance of debt securities; and (3) the issuance of preferred shares of beneficial interest ("Preferred Shares"). Additionally, the Fund may use certain derivatives and other financing instruments that have the economic effect of leverage by creating additional investment exposures, such as investments in inverse floating rate securities and reverse repurchase agreements. The amount and sources of leverage will vary depending on market conditions. See "Use of Leverage" for more information. |

---

##### [**Table of Contents**](#toc)
Currently, the Fund employs leverage through borrowings. There is no assurance that the Fund will continue to use leverage. The Fund's use of leverage may not work as planned or achieve its goals.

In pursuit of its investment objective, the Fund may reduce or increase the amount and type of leverage based upon changes in market conditions and composition of the Fund's holdings. The Fund's leverage ratio varies from time to time based upon such changes in the amount of leverage used and variations in the value of the Fund's holdings. So long as the net income received on the Fund's investments purchased with leverage proceeds exceeds the then current expense on any leverage, the investment of leverage proceeds will generate more net income than if the Fund had not used leverage. Under these circumstances, the excess net income will be available to pay higher distributions to Common Shareholders. However, if the net income received from the Fund's portfolio investments purchased with leverage is less than the then current expense on outstanding leverage, the Fund may be required to utilize other Fund assets to make expense payments on outstanding leverage, which may result in a decline in Common Share NAV and reduced net investment income available for distribution to Common Shareholders.

The Fund pays a management fee to Nuveen Fund Advisors (which in turn pays a portion of such fee to Nuveen Asset Management) based on a percentage of Managed Assets. Managed Assets include the proceeds realized and managed from the Fund's use of most types of leverage (excluding the leverage exposure attributable to the use of futures, swaps and similar derivatives). Because Managed Assets include the Fund's net assets as well as assets that are attributable to the Fund's investment of the proceeds of its leverage, the Fund's Managed Assets are greater than its net assets. Nuveen Fund Advisors and Nuveen Asset Management are responsible for using leverage to pursue the Fund's investment objective. Nuveen Fund Advisors and Nuveen Asset Management base their decision regarding whether and how much leverage to use for the Fund, and the terms of that leverage, on their assessment of whether such use of leverage is in the best interests of the Fund. However, a decision to employ or increase leverage has the effect, all other things being equal, of increasing Managed Assets, and in turn Nuveen Fund Advisors' and Nuveen Asset Management's management fees. Thus, Nuveen Fund Advisors and Nuveen Asset Management have a conflict of interest in determining whether to use or increase leverage. Nuveen Fund Advisors and Nuveen Asset Management seek to manage that conflict by recommending to the Board of Trustees to leverage the Fund (or increase such leverage) only when they determine that such action would be in the best interests of the Fund and its Common Shareholders, and by periodically reviewing with the Board of Trustees the Fund's performance and the impact of the use of leverage on that performance.<br>

##### [**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **Distributions**  | The Fund pays regular monthly cash distributions to Common Shareholders (stated in terms of a fixed cents per Common Share dividend distribution rate which may be set from time to time). The Fund intends to distribute all or substantially all of its net investment income each year through its regular monthly distributions and to distribute realized capital gains at least annually. In addition, in any monthly period, to maintain its declared per common share distribution amount, the Fund may distribute more or less than its net investment income during the period. In the event the Fund distributes more than its net investment income during any yearly period, such distributions may also include realized gains and/or a return of capital. To the extent that a distribution includes a return of capital the NAV per share may erode. If a distribution includes anything other than net investment income, the Fund provides a notice of the best estimate of its distribution sources at the time. See "Distributions." |
|  | The Fund reserves the right to change its distribution policy and the basis for establishing the rate of its monthly distributions at any time and may do so without prior notice to Common Shareholders. |

---

---

| | |
|:---|:---|
| **Custodian and Transfer Agent**  | State Street Bank and Trust Company serves as the Fund's custodian, and Computershare Inc. and Computershare Trust Company, N.A. serves as the Fund's transfer agent for the Common Shares. The corresponding agent for any Preferred Shares to be offered pursuant to this Prospectus will be identified in the related prospectus supplement. See "Custodian and Transfer Agent." |

---

---

| | |
|:---|:---|
| **Risk Factors**  | Investment in the Fund involves risk. The Fund is designed as a long-term investment and not as a trading vehicle. The Fund is not intended to be a complete investment program. Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Principal Risks of the Fund," as such principal risks may be supplemented from time to time, which is incorporated by reference herein, for a discussion of the principal risks you should consider before making an investment in the Fund. Any additional risks applicable to a particular offering of Securities will be set forth in the related prospectus supplement. |

---

##### [**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **Use of Proceeds**  | Unless otherwise specified in a prospectus supplement, the Fund will use the net proceeds from any offering of Securities, pursuant to this Prospectus, to make investments in accordance with the Fund's investment objective. See "Use of Proceeds." |

---

---

| | |
|:---|:---|
| **Federal Income Tax**  | The Fund has elected to be treated, and intends to qualify each year, as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"). To qualify for the favorable U.S. federal income tax treatment generally accorded to a RIC under Subchapter M of the Code the Fund must, among other requirements, derive in each taxable year at least 90% of its gross income from certain prescribed sources and satisfy a diversification test on a quarterly basis. If the Fund fails to satisfy the qualifying income or diversification requirements in any taxable year, the Fund may be eligible for relief provisions if the failures are due to reasonable cause and not willful neglect and if a penalty tax is paid with respect to each failure to satisfy the applicable requirements. Additionally, relief is provided for certain *de minimis* failures of the diversification requirements where the Fund corrects the failure within a specified period. In order to be eligible for the relief provisions with respect to a failure to meet the diversification requirements, the Fund may be required to dispose of certain assets. If these relief provisions were not available to the Fund and it were to fail to qualify for treatment as a RIC for a taxable year, all of its taxable income (including its net capital gain) would be subject to tax at the 21% regular corporate rate without any deduction for distributions to shareholders, and such distributions would be taxable as ordinary dividends to the extent of the Fund's current and accumulated earnings and profits. To qualify to pay exempt-interest dividends, which are treated as items of interest excludable from gross income for federal income tax purposes, at least 50% of the value of the total assets of the Fund must consist of obligations exempt from regular income tax as of the close of each quarter of the Fund's taxable year. If the proportion of taxable investments held by the Fund exceeds 50% of the Fund's total assets as of the close of any quarter of any Fund taxable year, the Fund will not for that taxable year satisfy the general eligibility test that otherwise permits it to pay exempt-interest dividends. |
|  | See "Fund Tax Risk" as contained in the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Principal Risks of the Fund—Fund Level and Other Risks." |

---

---

| | |
|:---|:---|
| **Governing Law**  | The Fund's Declaration of Trust (the "Declaration of Trust") is, and each Statement and Statement Supplement for Preferred Shares will be, governed by the laws of the Commonwealth of Massachusetts. |

---

##### [**Table of Contents**](#toc)
**SUMMARY OF FUND EXPENSES**

The purpose of the table below and the Examples below are to help you understand all fees and expenses that you, as a Common Shareholder, would bear directly or indirectly. The table shows the expenses of the Fund as a percentage of the average net assets applicable to Common Shares, and not as a percentage of total assets or Managed Assets.

---

| | | |
|:---|:---|:---|
| **Shareholder Transaction Expenses** |  |  |
| Maximum Sales Charge (as a percentage of offering price) | 1 | %\* |
| Dividend Reinvestment Plan Fees <sup>(1)</sup> | $2.5 |  |

---

\* The maximum sales charge for offerings made at-the-market is 1.00%. If the Common Shares are sold to or through underwriters in an offering that is not made at-the-market, the applicable Prospectus Supplement will set forth any other applicable sales load. Additionally, the applicable Prospectus Supplement will set forth the offering expenses (if any) borne by Fund common shareholders.

---

| | |
|:---|:---|
|  | **As a Percentage of Net Assets**<br> **Attributable to**<br> **Common Shares<sup>(2)</sup>** |
| **Annual Expenses** |  |
| Management Fees | 1.42% |
| Interest and Other Related Expenses <sup>(3)</sup> | 2.38% |
| Other Expenses <sup>(4)</sup> | 0.17% |
| Total Annual Expenses | 3.97% |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) You
 will be charged a $2.50 service charge and pay brokerage charges if you direct Computershare
 Inc. and Computershare Trust Company, N.A., as agent for the Common Shareholders (the
 "Plan Agent"), to sell your Common Shares held in a dividend reinvestment
 account.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Stated
 as annualized percentages of average net assets attributable to Common Shares for the
 six month period ended June 30, 2025 (unaudited).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Interest
 and Other Related Expenses reflect actual expenses and fees for leverage incurred by the
 Fund for the six month period ended June 30, 2025 (annualized). The types of leverage used
 by the Fund during the six month period ended June 30, 2025 (annualized) are described in
 the Fund Leverage and the Notes to Financial Statements sections of the Fund's [semi-annual report](https://www.sec.gov/Archives/edgar/data/1539337/000119312525196804/d64165dncsrs.htm) . Actual Interest and Other Related Expenses incurred in the future maybe higher
 or lower. If short-term market interest rates rise in the future, and if the Fund continues
 to maintain leverage, the cost of which is tied to short-term interest rates, the Fund's
 Interest and Other Related Expenses on its short-term borrowings can be expected to rise
 in tandem. The Fund's use of leverage will increase the amount of management fees paid
 to the Fund's adviser and sub-advisor(s).

&nbsp;&nbsp;&nbsp;&nbsp;(4) Other
Expenses is based on estimated amounts for the current fiscal year. Expenses attributable to the Fund's investments, if any, in
other investment companies are currently estimated not to exceed 0.01%. See "Investment Objective and Policies—Other Investment
Companies" in the SAI.

**Example** 

The following example illustrates the expenses, including the transaction fee (referred to as the "Maximum Sales Charge" in the Shareholder Transaction Expenses table above), if any, that a common shareholder would pay on a $1,000 investment that is held for the time periods provided in the table. The example assumes that all dividends and other distributions are reinvested in the Fund and that the Fund's Annual Expenses, as provided above, remain the same. The example also assumes a 5% annual return. Actual expenses may be greater or less than those assumed. Moreover, the Fund's actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

---

| | | | |
|:---|:---|:---|:---|
| **1 Year** | **3 Years** | **5 Years** | **10 Years** |
| $50 | $130 | $212 | $424 |

---

**The example should not be considered a representation of future expenses. Actual expenses may be greater or less than those shown above.**

**FINANCIAL HIGHLIGHTS** 

The financial highlights table is intended to help you understand the Fund's financial performance for the periods presented. Certain information reflects financial results for a single Common Share of the Fund. The information for the fiscal years ended December 31, 2024, December 31, 2023, December 31, 2022, December 31, 2021 and December 31, 2020 has been audited by KPMG LLP, an independent registered public accounting firm. The information with respect to the six months ended June 30, 2025 is unaudited and is included in the Fund's 2025 [Semi-Annual Report](https://www.sec.gov/Archives/edgar/data/1539337/000119312525196804/d64165dncsrs.htm). The report of KPMG LLP is included in the Fund's December 31, 2024 [Annual Report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm), which is incorporated by reference herein. The information in the table below for the fiscal years ended December 31, 2019, December 31, 2018, December 31, 2017, December 31, 2016 and December 31, 2015 is derived from the Fund's financial statements for the fiscal year ended December 31, 2019.

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Period Ended June 30 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 |
| **Per Share Operating** |  |  |  |  |  |  |  |  |  |  |  |
| **Performance** | **2025(e)** | **2024** | **2023** | **2022** | **2021** | **2020** | **2019** | **2018** | **2017** | **2016** | **2015** |
| &nbsp;&nbsp;&nbsp;Beginning Common Share Net Asset Value (NAV) | $13.19 | $13.69 | $13.57 | $17.41 | $15.84 | $20.04 | $16.48 | $19.61 | $18.09 | $17.27 | $19.84 |
| &nbsp;&nbsp;&nbsp;**Investment Operations:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Investment Income (Loss)(a) | 0.35 | 0.54 | 0.55 | 0.78 | 1.00 | 0.80 | 0.91 | 1.05 | 1.14 | 1.12 | 1.18 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Realized/Unrealized Gain (Loss) | 0.82 | 0.39 | 0.65 | (3.46) | 1.73 | (3.78) | 3.94 | (2.93) | 1.66 | 1.04 | (2.18) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 1.17 | 0.93 | 1.20 | (2.68) | 2.73 | (2.98) | 4.85 | (1.88) | 2.80 | 2.16 | (1.00) |
| &nbsp;&nbsp;&nbsp;**Less Distributions to Common Shareholders:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From Net Investment Income | (0.80) | (0.65) | (0.66) | (0.77) | (1.09) | (0.99) | (1.29) | (1.12) | (1.28) | (1.14) | (1.15) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From Accumulated Net Realized Gains |  |  |  |  |  |  |  |  |  |  | (0.04) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Return of Capital |  | (0.78) | (0.42) | (0.39) | (0.07) | (0.23) |  | (0.15) |  | (0.21) | (0.38) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | (0.80 | (1.43) | (1.08) | (1.16) | (1.16) | (1.22) | (1.29) | (1.27) | (1.28) | (1.35) | (1.57) |
| &nbsp;&nbsp;&nbsp;**Common Share:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discount Per Share Repurchased and Retired | $— | $— | $— (h) | $— | $— | $— (h) | $— | $0.02 | $— | $0.01 | $— (h) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ending NAV | $13.56 | $13.19 | $13.69 | $13.57 | $17.41 | $15.84 | $20.04 | $16.48 | $19.61 | $18.09 | $17.27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ending Share Price | $13.50 | $12.13 | $11.72 | $11.70 | $16.12 | $13.46 | $18.36 | $13.63 | $17.80 | $15.74 | $15.24 |
| &nbsp;&nbsp;&nbsp;**Common Share Total Returns:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on NAV(b) | 9.13 | 7.03% | 9.32% | (15.83)% | 17.73% | (14.15)% | 30.18% | (9.90)% | 15.81% | 12.82% | (5.39)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on Share Price(b) | 18.34 | 16.12% | 10.02% | (20.83)% | 29.09% | (19.31)% | 45.48% | (17.07)% | 21.62% | 12.37% | (11.72)% |
| &nbsp;&nbsp;&nbsp;**Common Share Supplemental Data/Ratios Applicable to Common Shares:** |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ending Net Assets (000) | $371865 | $361498 | $375319 | $372451 | $477911 | $434736 | $550464 | $452703 | $541875 | $176439 | $168755 |
| &nbsp;&nbsp;&nbsp;Ratios to Average Net Assets(c) |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses | 3.97 | 4.14% | 4.07% | 2.63% | 1.82% | 2.20% | 2.80% | 2.77% | 2.47% | 2.18% | 2.12% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Investment Income (Loss)(d) | 5.38 | 3.99% | 4.15% | 5.09% | 5.94% | 5.26% | 4.84% | 5.73% | 5.90% | 6.19% | 6.24% |
| &nbsp;&nbsp;&nbsp;Portfolio Turnover Rate | 36 | 80% | 59% | 71% | 73% | 102% | 90% | 92% | 100% | 107% | 96% |
| &nbsp;&nbsp;&nbsp;Borrowings at the End of Period: |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Outstanding (000)<sup>(f)</sup> | $170945 | $178945 | $151695 | $166985 | $197935 | $166035 | $222225 | $215225 | $225225 | $73275 | $74500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset Coverage Per $1,000 Share<sup>(g)</sup> | $3175 | $3020 | $3474 | $3230 | $3414 | $3618 | $3477 | $3103 | $3406 | $3408 | $3265 |

---

---

| | |
|:---|:---|
| (a) | Based on average shares outstanding. |
| (b) | Total Return Based on Common Share NAV is the combination of changes in common share NAV, reinvested distributions at Common Share NAV, if any. The last distribution declared in the period, which is typically paid on the first business day of the following month, is assumed to be reinvested at the ending NAV. The actual reinvest price for the last distribution declared in the period may often be based on the Fund's market price (and not its NAV), and therefore may be different from the price used in the calculation. Total returns are not annualized. |
|  | Total Return Based on Common Share Price is the combination of changes in the market price per share and the effect of reinvested distributions, if any, at the average price paid per share at the time of reinvestment. The last distribution declared in the period, which is typically paid on the first business day of the following month, is assumed to be reinvested at the ending market price. The actual reinvestment for the last distribution declared in the period may take place over several days, and in some instances may not be based on the market price, so the actual reinvestment price may be different from the price used in the calculation. Total returns are not annualized. |
| (c) | • Net Investment Income (Loss) ratios reflect income earned and expenses incurred on assets attributable to borrowings and/or reverse repurchase agreements, where applicable.<br> • The expense ratios reflect, among other things, all interest expense and other costs related to borrowings and/or reverse repurchase agreements and/or the interest expense deemed to have been paid by the Fund on the floating rate certificates issued by the special purpose trusts for the self-deposited inverse floaters held by the Fund, where applicable, as follows: |

---

---

| | |
|:---|:---|
|  | **Ratios of Interest Expense to Average Net Assets Applicable to Common Shares** |
| **<u>Period Ended June 30:</u>** | |
| 2025(e) | 2.38% |
| **<u>Year Ended December 31:</u>** |  |
| 2024 | 2.48% |
| 2023 | 2.53 |
| 2022 | 1.04 |
| 2021 | 0.34 |
| 2020 | 0.66 |
| 2019 | 1.28 |
| 2018 | 1.20 |
| 2017 | 0.82 |
| 2016 | 0.56 |
| 2015 | 0.52 |

---

(d) Includes voluntary compensation from Nuveen Fund Advisors.

(e) For the six months ended June 30, 2025. Unaudited.

(f) Aggregate Amount Outstanding: Aggregate amount outstanding represents the principal amount outstanding or liquidation preference, if applicable, as of the end of the relevant fiscal year.

(g) Asset Coverage Per $1,000: Asset coverage per $1,000 of debt is calculated by subtracting the Fund's liabilities and indebtedness not represented by senior securities from the Fund's total assets, dividing the results by the aggregate amount of the Fund's senior securities representing indebtedness then outstanding (if applicable), plus the aggregate of the involuntary liquidation preference of the outstanding preferred shares, if applicable, and multiplying the result by 1,000.

(h) Value rounded to zero.

\* Annualized.

**TRADING AND NET ASSET VALUE INFORMATION** 

The following table shows for the periods indicated: (i) the high and low sales prices for Common Shares reported as of the end of the day on the NYSE, (ii) the corresponding NAV per share, and (iii) the premium/(discount) to NAV per share at which the Common Shares were trading as of such date. The Fund's Common Shares have historically traded both at premiums and discounts in relation to the Fund's NAV per share. The Fund cannot predict whether its Common Shares will trade at a premium or discount to NAV in the future. The Board of Trustees has currently determined that, at least annually, it will consider action that might be taken to reduce or eliminate any material discount from NAV in respect of Common Shares, which may include the repurchase of such shares in the open market or in private transactions, the making of a tender offer for such shares at NAV, or the conversion of the Fund to an open-end investment company. The Fund cannot assure you that its Board of Trustees will decide to take any of these actions, or that share repurchases or tender offers will actually reduce market discount.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Closing Market Price per** | **Closing Market Price per** | **NAV per Common Share on** | **NAV per Common Share on** | **Premium/(Discount) on** | **Premium/(Discount) on** |
| | **Common Share** | **Common Share** | **Date of Market Price** | **Date of Market Price** | **Date of Market Price** | **Date of Market Price** |
| <br>**Fiscal Quarter Ended** | **High** | **Low** | **High** | **Low** | **High** | **Low** |
| December 2025 | $14.33 | $13.16 | $13.76 | $13.15 | 4.14% | 0.08% |
| September 2025 | $14.25 | $13.03 | $13.71 | $13.38 | 3.94% | (2.62)% |
| June 2025 | $13.50 | $11.26 | $13.56 | $12.32 | (0.44)% | (8.60)% |
| March 2025 | $13.14 | $12.04 | $13.36 | $12.91 | (1.65)% | (6.74)% |
| December 2024 | $13.61 | $11.95 | $14.02 | $12.97 | (2.92)% | (7.86)% |
| September 2024 | $13.67 | $12.21 | $14.54 | $13.21 | (5.98)% | (7.57)% |
| June 2024 | $12.21 | $10.86 | $13.18 | $12.66 | (7.36)% | (14.22)% |
| March 2024 | $12.12 | $11.35 | $13.68 | $13.25 | (11.40)% | (14.34)% |

---

The net asset value per Common Share, the market price, and percentage of premium/(discount) to net asset value per Common Share on January 13, 2026, was $13.56, $13.82 and 1.92%, respectively. As of January 13, 2026, the Fund had 27,448,277 Common Shares outstanding and net assets applicable to Common Shares of $372,305,531.

**THE FUND** 

The Fund is a diversified, closed-end management investment company registered under the 1940 Act. The Fund was organized as a Massachusetts business trust on January 10, 2012 and commenced investment operations on April 25, 2012. The Fund's Common Shares are listed on the NYSE under the symbol "JRI" Preferred Shares and/or Rights issued by the Fund may also be listed on a securities exchange.

The following provides information about the Fund's outstanding Common Shares and Preferred Shares as of January 13, 2026:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Title of Class** | **Amount<br>Authorized** | **Amount<br>Authorized** | **Amount Held<br>by the Fund or<br>for its Account** | **Amount Held<br>by the Fund or<br>for its Account** | **Amount<br>Outstanding** | **Amount<br>Outstanding** |
| Common Shares |  | Unlimited |  | 0 |  | 27448277 |
| Preferred Shares |  | Unlimited |  | 0 |  | 0 |

---

##### [**Table of Contents**](#toc)
**USE OF PROCEEDS** 

Unless otherwise specified in a prospectus supplement, the net proceeds from any offering will be invested in accordance with the Fund's investment objective and policies as stated below. The Fund currently anticipates that it will be able to invest substantially all of the net proceeds in investments that meet the Fund's investment objective and policies within approximately three months of the receipt of such proceeds. Pending investment, it is anticipated that the proceeds will be invested in short-term or long-term securities issued by the U.S. Government and its agencies or instrumentalities or in high-quality, short-term money market instruments.

**THE FUND'S INVESTMENTS** 

**Investment Objective and Policies** 

Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Investment Objective" and "—Investment Policies," as such investment objective and investment policies may be supplemented from time to time, which is incorporated by reference herein, for a discussion of the Fund's investment objective and policies.

**Portfolio Composition and Other Information** 

Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Investment Policies—Portfolio Contents," as such portfolio contents may be supplemented from time to time, which is incorporated by reference herein, for a discussion of the investments principally included in the Fund's portfolio. More detailed information about the Fund's portfolio investments are contained in the SAI under "The Fund's Investments."

**Portfolio Turnover** 

The Fund may engage in portfolio trading when considered appropriate, but short-term trading will not be used as the primary means of achieving the Fund's investment objective. For the fiscal year ended December 31, 2024, the Fund's portfolio turnover rate was 80%. For the six months ended June 30, 2025, the Fund's portfolio turnover rate was 36% (unaudited). However, there are no limits on the Fund's rate of portfolio turnover, and investments may be sold without regard to length of time held when, in Nuveen Asset Management's opinion, investment considerations warrant such action. A higher portfolio turnover rate would result in correspondingly greater brokerage commissions and other transactional expenses that are borne by the Fund. Although these commissions and expenses are not reflected in the Fund's "Annual Expenses," they will be reflected in the Fund's total return. In addition, high portfolio turnover may result in the realization of net short-term capital gains by the Fund which, when distributed to shareholders, will be taxable as ordinary income. See "Tax Matters."

**Other Policies** 

Certain investment policies specifically identified in the SAI as such are considered fundamental and may not be changed without shareholder approval. See "Investment Restrictions" in the SAI.

##### [**Table of Contents**](#toc)
**USE OF LEVERAGE**

The Fund uses leverage to pursue its investment objective. The Fund may source leverage through the issuance of "senior securities" as defined under the 1940 Act, which include (1) borrowings, including loans from financial institutions; (2) the issuance of debt securities; and (3) the issuance of Preferred Shares. Additionally, the Fund may use certain derivatives and other financing instruments that have the economic effect of leverage by creating additional investment exposures, such as investments in inverse floating rate securities and reverse repurchase agreements. See "Investment Restrictions" in the SAI. For a discussion of risks, see "Fund Level and Other Risks—Reverse Repurchase Agreement Risk," as such risk is contained in the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Principal Risks of the Fund."

Currently, the Fund employs leverage through borrowings. There is no assurance that the Fund will continue to use leverage. The Fund's use of leverage may not work as planned or achieve its goals.

The Fund may use derivatives, such as interest rate swaps with varying terms, in order to hedge duration risk or manage the interest rate expense associated with all or a portion of its leverage. Interest rate swaps are bi-lateral agreements whereby parties agree to exchange future payments, typically based upon the differential of a fixed rate and a variable rate, on a specified notional amount. Interest rate swaps can enable the Fund to effectively convert its variable leverage expense to fixed, or vice-versa. For example, if the Fund issues leverage having a short-term floating rate of interest, the Fund could use interest rate swaps to hedge against a rise in the short-term benchmark interest rates associated with its outstanding leverage. In doing so, the Fund would seek to achieve lower leverage costs, and thereby enhance Common Share distributions, over an extended period, which would be the result if short-term market interest rates on average exceed the fixed interest rate over the term of the swap. To the extent the fixed swap rate is greater than short-term market interest rates on average over the period, overall costs associated with leverage will be greater (and thereby reduce distributions to Common Shareholders) than if the Fund had not entered into the interest rate swap(s).

In pursuit of its investment objective, the Fund may reduce or increase the amount and type of leverage based upon changes in market conditions and composition of the Fund's holdings. The Fund's leverage ratio will vary from time to time based upon such changes in the amount of leverage used and variations in the value of the Fund's holdings. So long as the net income received from the Fund's investments purchased with leverage proceeds exceeds the then current expense of any leverage, the investment of the proceeds of leverage will generate more net income than if the Fund had not leveraged itself. Under these circumstances, the excess net income will be available to pay higher distributions to Common Shareholders. However, if the net income received from the Fund's portfolio investments purchased with the proceeds of leverage is less than the current expense of any leverage, the Fund may be required to utilize other Fund assets to make interest or dividend payments on its leveraging instruments which may result in a decline in Common Share NAV and reduced net investment income available for distribution to Common Shareholders.

The Fund pays a management fee to Nuveen Fund Advisors (which in turn pays a portion of such fee to Nuveen Asset Management) based on a percentage of Managed Assets. Managed Assets include the proceeds realized and managed from the Fund's use of most types of leverage (excluding the leverage exposure attributable to the use of futures, swaps and similar derivatives). Because Managed Assets include the Fund's net assets as well as assets that are attributable to the Fund's investment of the proceeds of its leverage, it is anticipated that the Fund's Managed Assets will be greater than its net assets. Nuveen Fund Advisors and Nuveen Asset Management are responsible for using leverage to pursue the Fund's investment objective. Nuveen Fund Advisors and Nuveen Asset Management will base their decision regarding whether and how much leverage to use for the Fund, and the terms of that leverage, on their assessment of whether such use of leverage is in the best interests of the Fund. However, a decision to employ or increase leverage will have the effect, all other things being equal, of increasing Managed Assets and in turn Nuveen Fund Advisors' and Nuveen Asset Management's management fees. Thus, Nuveen Fund Advisors and Nuveen Asset Management have a conflict of interest in determining whether to use or increase leverage, including the use of the Facility. Nuveen Fund Advisors and Nuveen Asset Management will seek to manage that conflict by using leverage only when they determine that it would be in the best interests of the Fund and its Common Shareholders, and by periodically reviewing with the Board of Trustees the Fund's performance and the Fund's degree of overall use of leverage and the impact of the use of leverage on that performance.

##### [**Table of Contents**](#toc)
The 1940 Act generally defines a "senior security" as any bond, debenture, note, or similar obligation or instrument constituting a security and evidencing indebtedness, and any stock of a class having priority over any other class as to distribution of assets or payment of dividends; however, the term does not include any promissory note or other evidence of indebtedness issued in consideration of any loan, extension, or renewal thereof, made for temporary purposes and in an amount not exceeding five percent of the value of the Fund's total assets. A loan shall be presumed to be for temporary purposes if it is repaid within 60 days and is not extended or renewed. Accordingly, "senior securities" include (i) the issuance of Preferred Shares; (ii) certain borrowings (including certain loans from financial institutions); and (iii) the issuance of debt securities.

Under the 1940 Act, the Fund is not permitted to issue "senior securities" that are Preferred Shares if, immediately after the issuance of Preferred Shares, the asset coverage ratio with respect to such Preferred Shares would be less than 200%. With respect to any such Preferred Shares, asset coverage means the ratio which the value of the total assets of the Fund, less all liabilities and indebtedness not represented by senior securities, bears to the aggregate amount of senior securities representing indebtedness of the Fund plus the aggregate liquidation preference of such Preferred Shares.

Under the 1940 Act, the Fund is not permitted to issue "senior securities representing indebtedness" if, immediately after the issuance of such senior securities representing indebtedness, the asset coverage ratio with respect to such senior securities would be less than 300%. "Senior securities representing indebtedness" include certain borrowings (including certain loans from financial institutions) and debt securities. "Senior securities representing indebtedness" may also include other investments or transactions in accordance with the 1940 Act, such as reverse repurchase agreements or similar financing transactions depending upon their treatment under Rule 18f-4 of the 1940 Act. In accordance with Rule 18f-4 under the 1940 Act, when the Fund engages in reverse repurchase agreements or similar financing transactions, such as transactions in inverse floating rate securities, the Fund may either (i) maintain asset coverage in accordance with Section 18 of the 1940 Act with respect to such transactions and any other senior securities, including Preferred Shares and borrowings, or (ii) treat such transactions as "derivatives transactions" and comply with Rule 18f-4 with respect to such transactions. With respect to any such senior securities representing debt, asset coverage means the ratio which the value of the total assets of the Fund, less all liabilities and indebtedness not represented by senior securities (as defined in the 1940 Act), bears to the aggregate amount of such borrowing represented by senior securities issued by the Fund.

If the Fund issues senior securities and the asset coverage with respect to such senior securities declines below the required ratios discussed above (as a result of market fluctuations or otherwise), the Fund may sell portfolio securities when it may be disadvantageous to do so.

Certain types of leverage used by the Fund may result in the Fund being subject to certain covenants, asset coverage or other portfolio composition limits by its lenders, debt or preferred securities purchasers, rating agencies that may rate the debt or preferred securities, or reverse repurchase counterparties. Such limitations may be more stringent than those imposed by the 1940 Act and may impact whether the Fund is able to maintain its desired amount of leverage. At this time Nuveen Fund Advisors does not believe that any such potential investment limitations will impede it from managing the Fund's portfolio in accordance with its investment objective and policies.

Utilization of leverage is a speculative investment technique and involves certain risks to the Common Shareholders, including increased variability of the Fund's net income, distributions and NAV in relation to market changes. See "Leverage Risk," as such risk is contained in the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Principal Risks of the Fund—Fund Level and Other Risks." There is no assurance that the Fund will use leverage or that the Fund's use of leverage will work as planned or achieve its goals.

**Effects of Leverage** 

Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Effects of Leverage," as such may be supplemented from time to time, which is incorporated by reference herein, for a discussion of the effects of leverage.

##### [**Table of Contents**](#toc)
**RISK FACTORS** 

Risk is inherent in all investing. Investing in any investment company security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part or all of your investment. Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Current Investment Objectives, Investment Policies and Principal Risks of the Fund—Principal Risks of the Fund," as such principal risks may be supplemented from time to time, which is incorporated by reference herein, for a discussion of the principal risks you should consider before making an investment in the Fund. Any additional risks applicable to a particular offering of Securities will be set forth in the related prospectus supplement.

**MANAGEMENT OF THE FUND** 

**Trustees and Officers** 

The Board of Trustees is responsible for the management of the Fund, including supervision of the duties performed by Nuveen Fund Advisors and Nuveen Asset Management. The names and business addresses of the trustees and officers of the Fund and their principal occupations and other affiliations during the past five years are set forth under "Management of the Fund" in the SAI.

**Investment Adviser, Sub-Adviser and Portfolio Managers** 

*Investment Adviser.* Nuveen Fund Advisors, LLC, the Fund's investment adviser, is responsible for overseeing the Fund's overall investment strategy and implementation. Nuveen Fund Advisors offers advisory and investment management services to a broad range of investment company clients. Nuveen Fund Advisors has overall responsibility for management of the Fund, oversees the management of the Fund's portfolio, manages the Fund's business affairs and provides certain clerical, bookkeeping and other administrative services. Nuveen Fund Advisors is located at 333 West Wacker Drive, Chicago, Illinois 60606. Nuveen Fund Advisors is an indirect subsidiary of Nuveen, the investment management arm of TIAA. TIAA is a life insurance company founded in 1918 by the Carnegie Foundation for the Advancement of Teaching and is the companion organization of College Retirement Equities Fund. As of December 31, 2025, Nuveen managed approximately $1.4 trillion in assets, of which approximately $157.4 billion was managed by Nuveen Fund Advisors.

*Sub-Adviser.* Nuveen Asset Management, LLC, located at 333 West Wacker Drive, Chicago, Illinois 60606, serves as the Fund's sub-adviser pursuant to a sub-advisory agreement between Nuveen Fund Advisors and Nuveen Asset Management (the "Sub-Advisory Agreement"). Nuveen Asset Management, a registered investment adviser, is a wholly owned subsidiary of Nuveen Fund Advisors. Nuveen Asset Management oversees day-to-day investment operations of the Fund. Pursuant to the Sub-Advisory Agreement, Nuveen Asset Management is compensated for the services it provides to the Fund with a portion of the management fee Nuveen Fund Advisors receives from the Fund. Nuveen Fund Advisors and Nuveen Asset Management retain the right to reallocate investment advisory responsibilities and fees between themselves in the future.

*Portfolio Managers.* Nuveen Asset Management is responsible for the execution of specific investment strategies and day-to-day investment operations of the Fund. Nuveen Asset Management manages the Nuveen funds using a team of analysts and portfolio managers that focuses on a specific group of funds. The day-to-day operation of the Fund and the execution of its specific investment strategies is the primary responsibility of Brenda Langenfeld, CFA, Tryg Sarsland, Benjamin Kerl, Noah Hauser, CFA and James Kim, the designated portfolio managers of the Fund. Ms. Langenfeld and Mr. Sarsland have served as portfolio managers of the Fund since April 2015, Mr. Kerl has served as portfolio manager of the Fund since October 2021, Mr. Hauser has served as portfolio manager of the Fund since March 2024, and Mr. Kim has served as portfolio manager of the Fund since February 2025.

##### [**Table of Contents**](#toc)
**Brenda A. Langenfeld**, CFA, is a portfolio manager for Nuveen's global fixed income team and a member of the preferred securities sector team. She is the lead manager for Nuveen's preferred and income-focused closed-end funds and portfolio manager of the Preferred Securities and Income strategy. She joined the preferred securities sector team in 2011. Brenda has been a co-manager for the Real Asset Income strategy since 2015, which invests in income generating debt and equity securities from both the real estate and infrastructure segments. In 2020 she became co-manager of the Credit Income strategy. Prior to her portfolio management roles, Brenda was a member of the high-grade credit sector team, responsible for trading corporate bonds. Previously, she was a member of the securitized debt sector team, trading mortgage-backed securities, asset-backed securities and commercial mortgage-backed securities.

**Tryg T. Sarsland**, Managing Director and Director of Global Infrastructure Research at Nuveen, is a portfolio manager for Nuveen's public global infrastructure and real asset income strategies. Offerings span both the traditional public real assets and responsible investing-focused investment styles. In addition, he is the director of research - infrastructure, overseeing direct management of the U.S.-based equity research analysts dedicated to global infrastructure and real asset income. Tryg also maintains analyst responsibilities for the global infrastructure and real asset income strategies, specializing in non-U.S. utilities. Before joining the firm in 2011, he was vice president and director of project finance at National Wind, LLC, where he spearheaded the development, procurement and investment of funds for wind energy projects. He was also vice president with Meridian Companies, LLC, and Standard Chartered Bank.

**Benjamin T. Kerl**, Managing Director at Nuveen, is a portfolio manager for Nuveen's global real estate securities and global real estate carbon reduction strategies. He is also head of real estate investments for the Real Assets investment team at Nuveen. He specializes in real estate equities in the U.K., Europe and Canada. From 2012 through 2017, Ben also covered the multi-family and healthcare sectors for the firm's Real Estate Securities strategy. Ben began working in the investment industry in 2012 when he joined the firm. Before joining the firm, he worked for eight years in the real estate and renewable energy industries. Most recently, Ben was an independent consultant providing project development services to national and international wind energy developers. He started his career as a real estate development manager at Lander Group, where he managed infill multifamily and commercial projects from 2005 to 2007.

**Noah P. Hauser**, CFA, serves as Head of Infrastructure Investments for Nuveen, overseeing strategy, investment process and performance of the firm's infrastructure platform and also serves as a portfolio manager for Nuveen's public global infrastructure strategies. Offerings span both the traditional public real assets and responsible investing-focused investment styles. Previously, Noah served as a senior research analyst and head of North American utilities. Prior to joining Nuveen in 2015, Noah worked at Xcel Energy as the director of investor relations. Previously, he was a buy-side investment analyst for an energy-focused, relative value equity strategy at Decade Capital Management, a Millennium Group company. In that role, Noah performed detailed analysis on regulated utilities, independent power producers, pipelines and master limited partnerships. He began his career working as a sell-side equity analyst covering regulated utilities and power companies at Barclays Capital and Lehman Brothers. Noah began working in the investment industry in 2008.

**James Kim** is a portfolio manager for Nuveen's leveraged finance team with a focus on the management of high yield mandates. James is the lead manager of the High Yield Income strategy and a co-manager on the High Yield, Real Asset Income and Credit Income strategies. He is also head of special situations, leading workouts and opportunistic investing for the leveraged finance platform. Previously, James was co-head of global fixed income research and head of the leveraged finance research team, overseeing its daily investment process. He also served as the co-head of research at Nuveen affiliate Symphony Asset Management, leading the firm's research team, daily investment process and opportunistic investments across its various mandates. Prior to this, he was a distressed generalist and an industry analyst responsible for a number of different industries, including energy, power, metals & mining and chemicals, providing long and short ideas across the capital structure. Prior to joining the firm, James was an associate at Greywolf Capital in its special situations group and an analyst at Watershed Asset Management. He began his career at Goldman Sachs, as an investment banking analyst both in the Strategy Group and Energy & Power Group.

Additional information about the Portfolio Managers' compensation, other accounts managed by the Portfolio Managers and the Portfolio Managers' ownership of securities in the Fund is provided in the SAI. The SAI is available free of charge by calling (800) 257-8787 or by visiting the Fund's website at www.nuveen.com. The information contained in, or that can be accessed through, the Fund's website is not part of this Prospectus or the SAI, except to the extent specifically incorporated by reference herein or in the SAI.

##### [**Table of Contents**](#toc)
**Investment Management and Sub-Advisory Agreements** 

*Investment Management Agreement.* Pursuant to an investment management agreement between Nuveen Fund Advisors and the Fund (the "Investment Management Agreement"), the Fund has agreed to pay an annual management fee for the services and facilities provided by Nuveen Fund Advisors, payable on a monthly basis, based on the sum of a fund-level fee and a complex-level fee, as described below.

*Fund-Level Fee.* The annual fund-level fee for the Fund, payable monthly, is calculated according to the following schedule:

---

| | |
|:---|:---|
| **Average Daily Managed Assets\*** | <br> **Fund Level**<br> **Fee Rate** |
| For the first $500 million | 0.8000% |
| For the next $500 million | 0.7750% |
| For the next $500 million | 0.7500% |
| For the next $500 million | 0.7250% |
| For managed assets over $2 billion | 0.7000% |

---

*Complex-Level Fee.* The overall complex-level fee, payable monthly, begins at a maximum rate of 0.1600% of the Fund's average daily managed assets, with breakpoints for eligible complex-level assets above $124.3 billion. Therefore, the maximum management fee rate for the Fund is the Fund-level fee plus 0.1600%. The current overall complex-level fee schedule is as follows:

---

| | |
|:---|:---|
| **Complex-Level Asset Breakpoint Level\*** | **Complex-Level Fee** |
| For the first $124.3 billion | 0.1600% |
| For the next $75.7 billion | 0.1350% |
| For the next $200 billion | 0.1325% |
| For eligible assets over $400 billion | 0.1300% |

---

\* See "Investment Adviser, Sub-Adviser and Portfolio Managers" in the SAI for more detailed information about the complex-level fee and eligible complex-level assets.

As of December 31, 2025, the complex-level fee rate for the Fund was 0.1560%.

In addition to the fee of Nuveen Fund Advisors, the Fund pays all other costs and expenses of its operations, including compensation of its trustees (other than those affiliated with Nuveen Fund Advisors and Nuveen Asset Management), custodian, transfer agency and dividend disbursing expenses, legal fees, expenses of independent auditors, expenses of repurchasing shares, expenses associated with any borrowings, expenses of issuing any Preferred Shares, expenses of preparing, printing and distributing shareholder reports, notices, proxy statements and reports to governmental agencies, and taxes, if any. All fees and expenses are accrued daily and deducted before payment of dividends to investors.

A discussion regarding the basis for the Board of Trustees' most recent approval of the Investment Management Agreement for the Fund may be found in the Fund's [semi-annual report](https://www.sec.gov/Archives/edgar/data/1539337/000119312525196804/d64165dncsrs.htm) to shareholders dated June 30, 2025.

*Sub-Advisory Agreement.* Pursuant to the Sub-Advisory Agreement, Nuveen Asset Management will receive from Nuveen Fund Advisors a management fee equal to 50% of Nuveen Fund Advisors' net management fee from the Fund. Nuveen Fund Advisors and Nuveen Asset Management retain the right to reallocate investment advisory responsibilities and fees between themselves in the future.

A discussion regarding the basis for the Board's most recent decision to approve the Sub-Advisory Agreement for the Fund may be found in the Fund's [semi-annual report](https://www.sec.gov/Archives/edgar/data/1539337/000119312525196804/d64165dncsrs.htm) to shareholders dated June 30, 2025.

##### [**Table of Contents**](#toc)
**Control Persons and Principal Holders of Common Shares**

Except as noted below in the table, to the Fund's knowledge, no persons own of record or beneficially, five percent or more of any class of shares of the Fund as of December 31, 2025:

---

| | | |
|:---|:---|:---|
| **Class** | **Number of<br> Shares Owned<br> of Class** | &nbsp;&nbsp;&nbsp;**Percentage<br> Owned<br> of Class** |
| Common Shares First Trust Portfolios L.P.<sup>(a)</sup><br> 120 East Liberty Drive, Suite 400,<br> Wheaton, Illinois 60187 | 1400711 | &nbsp;&nbsp;&nbsp;5.11% |
| First Trust Advisors L.P. <sup>(a)</sup><br> 120 East Liberty Drive, Suite 400,<br> Wheaton, Illinois 60187 |  |  |

---

The Charger Corporation<sup>(a)</sup> 120 East Liberty Drive, Suite 400, Wheaton, Illinois 60187

\* The information contained in this table is based on Schedule 13D and 13G filings made on or before December 31, 2025.

(a) First Trust Portfolios L.P., First Trust Advisors L.P. and The Charger Corporation filed their Schedule 13G jointly and did not differentiate holdings as between each entity.

**NET ASSET VALUE** 

The Fund's NAV per Common Share is determined as of the close of trading (normally 4:00 p.m., Eastern Time) on each day the NYSE is open for business. NAV is calculated by taking the market value of the Fund's total assets, less all liabilities, and dividing by the total number of Common Shares outstanding. The result, rounded to the nearest cent, is the NAV per share.

The Fund utilizes independent pricing services approved by its valuation designee to value portfolio instruments at their market value. Independent pricing services typically value non-equity portfolio instruments utilizing a range of market-based inputs and assumptions, including market quotations obtained from broker-dealers making markets in such instruments, cash flows and transactions for comparable instruments. In pricing certain securities, particularly less liquid and lower quality securities, the pricing services may consider information about a security, its issuer or market activity provided by Nuveen Fund Advisors or Nuveen Asset Management.

The valuations for fixed-income securities and certain derivative instruments are typically the prices supplied by independent third party pricing services, which may use market prices or broker/dealer quotations or a variety of fair valuation techniques and methodologies.

For non-U.S. traded investments whose principal local markets close before the close of the NYSE, the Fund may adjust the local closing price based upon such factors as developments in non-U.S. markets, the performance of U.S. securities markets and the performance of instruments trading in U.S. markets that represent non-U.S. investments. The Fund may rely on an independent fair valuation service in making any such fair value determinations. If the Fund holds portfolio instruments that are primarily listed on non-U.S. exchanges, the value of such instruments may change on days when the Fund's NAV is calculated.

If a price cannot be obtained from a pricing service or other pre-approved source, or if the Fund's valuation designee deems such price to be unreliable, or if a significant event occurs after the close of the local market but prior to the time at which the Fund's NAV is calculated, a portfolio instrument will be valued at its fair value as determined in good faith by the Fund's valuation designee. The Fund's valuation designee may determine that a price is unreliable in various circumstances. For example, a price may be deemed unreliable if it has not changed for an identified period of time, or has changed from the previous day's price by more than a threshold amount, and recent transactions and/or broker dealer price quotations differ materially from the price in question.

The Board of Trustees has designated Nuveen Fund Advisors as the Fund's valuation designee pursuant to Rule 2a-5 under the 1940 Act and delegated to Nuveen Fund Advisors the day-to-day responsibility of making fair value determinations. All fair value determinations made by Nuveen Fund Advisors are subject to review by the Board of Trustees. As a general principle, the fair value of a portfolio instrument is the amount that an owner might reasonably expect to receive upon the instrument's current sale. A range of factors and analysis may be considered when determining fair value, including relevant market data, interest rates, credit considerations and/or issuer specific news. However, fair valuation involves subjective judgments, and it is possible that the fair value determined for a portfolio instrument may be materially different from the value that could be realized upon the sale of that instrument.

**DISTRIBUTIONS** 

The Fund pays regular monthly cash distributions to Common Shareholders (stated in terms of a fixed cents per Common Share dividend distribution rate which may be set from time to time). The Fund intends to distribute all or substantially all of its net investment income each year through its regular monthly distributions and to distribute realized capital gains at least annually. In addition, in any monthly period, to maintain its declared per common share distribution amount, the Fund may distribute more or less than its net investment income during the period. In the event the Fund distributes more than its net investment income during any yearly period, such distributions may also include realized gains and/or a return of capital.

To the extent that a distribution includes a return of capital the NAV per share may erode. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."

##### [**Table of Contents**](#toc)
If the Fund's distribution includes anything other than net investment income, the Fund will provide a notice to Common Shareholders of its best estimate of the distribution sources at the time of the distribution. These estimates may not match the final tax characterization (for the full year's distributions) contained in the Common Shareholders' 1099-DIV forms after the end of the year.

While the Fund intends to distribute all realized capital gains at least annually, the Fund may elect to retain all or a portion of any net capital gain (which is the excess of net long-term capital gain over net short-term capital loss) otherwise allocable to Common Shareholders and pay U.S. federal income tax on the retained gain. As provided under U.S. federal income tax law, Common Shareholders of record as of the end of the Fund's taxable year will include their share of the retained net capital gain in their income for the year as a long-term capital gain (regardless of their holding period in the common shares), and will be entitled to an income tax credit or refund for the federal income tax deemed paid on their behalf by the Fund. If the Fund's total distributions during a given year is an amount that exceeds the Fund's current and accumulated earnings and profits, the excess would be treated by Common Shareholders as return of capital for federal income tax purposes to the extent of the Common Shareholder's basis in their shares and thereafter as capital gain.

Distributions will be reinvested in additional shares under the Fund's Dividend Reinvestment Plan unless a shareholder elects to receive cash. The Fund reserves the right to change its distribution policy and the basis for establishing the rate of its monthly distributions at any time and may do so without prior notice to Common Shareholders.

**DIVIDEND REINVESTMENT PLAN** 

Please refer to the section of the Fund's most recent [annual report](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR entitled "Shareholder Update—Dividend Reinvestment Plan," which is incorporated by reference herein, for a discussion of the Fund's dividend reinvestment plan.

**PLAN OF DISTRIBUTION** 

The Fund may offer and sell Securities from time to time on an immediate, continuous or delayed basis, in one or more offerings under this Prospectus and a related prospectus supplement, on terms to be determined at the time of the offering. The Fund may offer and sell such Securities directly to one or more purchasers, to or through underwriters, through dealers or agents that the Fund designates from time to time, or through a combination of these methods. Sales of Securities may be made in transactions that are deemed to be "at the market" as defined in Rule 415 under the Securities Act of 1933, as amended (the "1933 Act"), including sales made directly on the NYSE or sales made to or through a market maker other than on an exchange.

The prospectus supplement relating to any offering of Securities will describe the terms of such offering, including, as applicable:

● the names of any agents, underwriters or dealers;

● any sales loads, underwriting discounts and commissions or agency fees and
other items constituting underwriters' or agents' compensation;

● any discounts, commissions, fees or concessions allowed or reallowed or paid to dealers or agents;

● the public offering or purchase price of the offered Securities, the estimated net proceeds the Fund will receive from the sale and the use of proceeds; and

● any securities exchange on which the offered Securities may be listed.

The prospectus supplement relating to any Rights offering will set forth the number of Common Shares issuable upon the exercise of each Right (or number of Rights) and the other terms of such Rights offering.

##### [**Table of Contents**](#toc)
**Direct Sales** 

The Fund may offer and sell Securities directly to, and solicit offers from, institutional investors or others who may be deemed to be underwriters as defined in the 1933 Act for any resales of Securities. In this case, no underwriters or agents would be involved. The Fund may use electronic media, including the Internet, to sell offered Securities directly. The Fund will describe the terms of any of those sales in a prospectus supplement.

**By Agents** 

The Fund may offer and sell Securities through an agent or agents designated by the Fund from time to time. An agent may sell Securities it has purchased from the Fund as principal to other dealers for resale to investors and other purchasers, and may reallow all or any portion of the discount received in connection with the purchase from the Fund to the dealers. After the initial offering of Securities, the offering price (in the case of Securities to be resold at a fixed offering price), the concession and the discount may be changed.

**By Underwriters** 

If any underwriters are involved in the offer and sale of Securities, such Securities will be acquired by the underwriters and may be resold by them, either at a fixed public offering price established at the time of offering or from time to time in one or more negotiated transactions or otherwise, at prices related to prevailing market prices determined at the time of sale. Unless otherwise set forth in the applicable prospectus supplement, the obligations of the underwriters to purchase Securities will be subject to conditions precedent and the underwriters will be obligated to purchase all Securities described in the prospectus supplement if any are purchased. Any initial public offering price and any discounts or concessions allowed or re-allowed or paid to underwriters may be changed from time to time.

In connection with an offering of Common Shares, if a prospectus supplement so indicates, the Fund may grant the underwriters an option to purchase additional Common Shares at the public offering price, less the underwriting discounts and commissions, within 45 days from the date of the prospectus supplement, to cover any overallotments.

**By Dealers** 

The Fund may offer and sell Securities from time to time through one or more dealers who would purchase the securities as principal. The dealers then may resell the offered Securities to the public at fixed or varying prices to be determined by those dealers at the time of resale. The Fund will set forth the names of the dealers and the terms of the transaction in the prospectus supplement.

**General** 

Any underwriters, dealer or agent participating in an offering of Securities may be deemed to be an "underwriter," as that term is defined in the 1933 Act, of Securities so offered and sold, and any discounts and commission received by them, and any profit realized by them on resale of the offered Securities for whom they act as agent, may be deemed to be underwriting discounts and commissions under the 1933 Act.

Underwriters, dealers and agents may be entitled, under agreements entered into with the Fund, to indemnification by the Fund against some liabilities, including liabilities under the 1933 Act.

The Fund may offer to sell Securities either at a fixed price or at prices that may vary, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

##### [**Table of Contents**](#toc)
To facilitate an offering of Common Shares in an underwritten transaction and in accordance with industry practice, the underwriters may engage in transactions that stabilize, maintain, or otherwise affect the market price of the Common Shares or any other Security. Those transactions may include overallotment, entering stabilizing bids, effecting syndicate covering transactions, and reclaiming selling concessions allowed to an underwriter or a dealer.

● An overallotment in connection with an offering creates a short position in the Common Shares for the underwriter's own account.

● An underwriter may place a stabilizing bid to purchase the Common Shares for the purpose of pegging, fixing, or maintaining the price of the Common Shares.

● Underwriters may engage in syndicate covering transactions to cover overallotments or to stabilize the price of the Common Shares by bidding for, and purchasing, the Common Shares or any other Securities in the open
market in order to reduce a short position created in connection with the offering.

● The managing underwriter may impose a penalty bid on a syndicate member to reclaim a selling concession in connection with an offering when the Common Shares originally sold by the syndicate member are purchased in
syndicate covering transactions or otherwise.

Any of these activities may stabilize or maintain the market price of the Securities above independent market levels. Underwriters are not required to engage in these activities and may end any of these activities at any time.

In connection with any Rights offering, the Fund may also enter into a standby underwriting arrangement with one or more underwriters pursuant to which the underwriter(s) will purchase Common Shares remaining unsubscribed for after the Rights offering.

Unless otherwise indicated in the prospectus supplement, each series of offered Preferred Shares will be a new issue of securities for which there currently is no market. Any underwriters to whom Preferred Shares are sold for public offering and sale may make a market in such Preferred Shares as permitted by applicable laws and regulations, but such underwriters will not be obligated to do so, and any such market making may be discontinued at any time without notice. Accordingly, there can be no assurance as to the development or liquidity of any market for the Preferred Shares.

Underwriters, agents and dealers may engage in transactions with or perform services, including various investment banking and other services, for the Fund and/or any of the Fund's affiliates in the ordinary course of business.

The maximum amount of compensation to be received by any Financial Industry Regulatory Authority ("FINRA") member or independent broker-dealer will not exceed the applicable FINRA limit for the sale of any securities being offered pursuant to Rule 415 under the Securities Act. We will not pay any compensation to any underwriter or agent in the form of warrants, options, consulting or structuring fees or similar arrangements.

To the extent permitted under the 1940 Act and the rules and regulations promulgated thereunder, the underwriters may from time to time act as a broker or dealer and receive fees in connection with the execution of the Fund's portfolio transactions after the underwriters have ceased to be underwriters and, subject to certain restrictions, each may act as a broker while it is an underwriter.

A prospectus and accompanying prospectus supplement in electronic form may be made available on the websites maintained by underwriters. The underwriters may agree to allocate a number of Securities for sale to their online brokerage account holders. Such allocations of Securities for Internet distributions will be made on the same basis as other allocations. In addition, Securities may be sold by the underwriters to securities dealers who resell Securities to online brokerage account holders.

##### [**Table of Contents**](#toc)
**DESCRIPTION OF SHARES** 

**Common Shares** 

The Declaration of Trust authorizes the issuance of an unlimited number of Common Shares. The Common Shares have a par value of $0.01 per share and, subject to the rights of holders of any Preferred Shares, have equal rights to the payment of dividends and the distribution of assets upon liquidation. The Common Shares when issued, are fully paid and, subject to matters discussed in "Certain Provisions in the Declaration of Trust and By-Laws," non-assessable, and have no preemptive or conversion rights or rights to cumulative voting. A copy of the Declaration of Trust is filed with the SEC as an exhibit to the Fund's registration statement of which this Prospectus is a part.

Each whole Common Share has one vote with respect to matters submitted for a vote by the Fund's Common Shareholders and on which the shareholder is entitled to vote, and each fractional share shall be entitled to a proportional fractional vote consistent with the requirements of the 1940 Act and the rules promulgated thereunder, and will vote together as a single class. Whenever the Fund incurs borrowings and/or Preferred Shares are outstanding, Common Shareholders will not be entitled to receive any cash distributions from the Fund unless all interest on such borrowings has been paid and all accumulated dividends on Preferred Shares have been paid, and unless asset coverage (as defined in the 1940 Act) with respect to any borrowings would be at least 300% after giving effect to the distributions and asset coverage (as defined in the 1940 Act) with respect to Preferred Shares would be at least 200% after giving effect to the distributions. See "—Preferred Shares" below.

The Common Shares are listed on the NYSE and trade under the ticker symbol "JRI" The Fund intends to hold annual meetings of shareholders so long as the Common Shares are listed on a national securities exchange and such meetings are required as a condition to such listing. The Fund does not issue share certificates.

Unlike open-end funds, closed-end funds like the Fund do not provide daily redemptions. Rather, if a shareholder determines to buy additional Common Shares or sell shares already held, the shareholder may conveniently do so by trading on the exchange through a broker or otherwise. Common shares of closed-end investment companies may frequently trade on an exchange at prices lower than NAV. Common shares of closed-end investment companies like the Fund have during some periods traded at prices higher than NAV and have during other periods traded at prices lower than NAV.

Because the market value of the Common Shares may be influenced by such factors as distribution levels (which are in turn affected by expenses), call protection, dividend stability, portfolio credit quality, NAV, relative demand for and supply of such shares in the market, general market and economic conditions, and other factors beyond the control of the Fund, the Fund cannot assure you that Common Shares will trade at a price equal to or higher than NAV in the future. The Common Shares are designed primarily for long-term investors, and investors in the Common Shares should not view the Fund as a vehicle for trading purposes. See "Repurchase of Fund Shares; Conversion to Open-End Fund."

**Preferred Shares** 

The Fund's Declaration of Trust authorizes the issuance of an unlimited number of Preferred Shares in one or more classes or series, with rights as determined by the Board of Trustees, by action of the Board of Trustees without the approval of the Common Shareholders. The Fund currently has no Preferred Shares outstanding. The discussion below generally describes the rights of the holders of Preferred Shares, although the terms of any Preferred Shares that may be issued by the Fund may be the same as, or different from, the terms described below, subject to the applicable Statement, applicable law and the Declaration of Trust.

##### [**Table of Contents**](#toc)
Under the 1940 Act, the Fund is not permitted to issue "senior securities" that are Preferred Shares if, immediately after the issuance of Preferred Shares, the asset coverage ratio would be less than 200%. See "Use of Leverage." Additionally, the Fund will generally not be permitted to purchase any of its Common Shares or declare dividends (except a dividend payable in Common Shares) or other distributions on its Common Shares unless, at the time of such purchase or declaration, the asset coverage ratio with respect to such Preferred Shares, after taking into account such purchase or distribution, is at least 200%. Preferred Shares issued by the Fund have priority over the Common Shares.

For so long as any Preferred Shares are outstanding, the Fund will not: (1) declare or pay any dividend or other distribution (other than a dividend or distribution paid in Common Shares) in respect of the Common Shares, (2) call for redemption, redeem, purchase or otherwise acquire for consideration any Common Shares, or (3) pay any proceeds of the liquidation of the Fund in respect of the Common Shares, unless, in each case, (A) immediately thereafter, the Fund shall be in compliance with the 200% asset coverage limitations set forth under the 1940 Act after deducting the amount of such dividend or other distribution or redemption or purchase price or liquidation proceeds and (B) all cumulative dividends and other distributions of shares of all series of Preferred Shares of the Fund due on or prior to the date of the applicable dividend, distribution, redemption, purchase or acquisition shall have been declared and paid.

*Dividends and Distributions and Priority of Payment*

If the Fund issues Preferred Shares, the Fund's Preferred Shares will rank equally with each other and have priority over the Common Shares as to the payment of dividends and other distributions. The holders of Preferred Shares of each series will be entitled to receive, when, as and if declared by the Board, out of funds legally available therefor in accordance with the Declaration of Trust and applicable law, cumulative cash dividends at the dividend rate for the Preferred Shares of such series payable on the dividend payment dates with respect to the Preferred Shares of such series. Holders of Preferred Shares will not be entitled to any dividend, whether payable in cash, property or shares, in excess of full cumulative dividends on the Preferred Shares. No interest, or sum of money in lieu of interest, shall be payable in respect of any dividend payment or payments on Preferred Shares which may be in arrears, and no additional sum of money will be payable in respect of such arrearage. Dividends on a series of Preferred Shares may be determined at a fixed rate, by reference to an index or pursuant to a formula, established by a remarketing agent or otherwise. Dividends may be subject to a maximum rate as set forth in the applicable statement establishing and fixing the rights and preferences of such Preferred Shares.

*Liquidation Preference* 

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Fund, holders of Preferred Shares would be entitled to receive a preferential liquidating distribution (expected to equal the original purchase price per share plus accumulated and unpaid dividends thereon, whether or not earned or declared) before any distribution of assets is made to Common Shareholders. After payment of the full amount of the liquidating distribution to which they are entitled, holders of Preferred Shares will not be entitled to any further participation in any distribution of assets by the Fund. A consolidation or merger of the Fund with or into another entity or a sale of all or substantially all of the assets of the Fund shall not be deemed to be a liquidation, dissolution or winding up of the Fund.

*Voting Rights* 

In connection with any issuance of Preferred Shares, the Fund must comply with Section 18(i) of the 1940 Act, which requires, among other things, that Preferred Shares be voting shares and have equal voting rights with Common Shares. Except with respect to certain matters affecting only the holders of the Preferred Shares and except as discussed further below, holders of Preferred Shares vote together with Common Shareholders as a single class on matters submitted to Fund shareholders.

In connection with the election of the Fund's trustees, holders of Preferred Shares, voting as a separate class, are entitled to elect two of the Fund's trustees, and the remaining trustees are elected by Common Shareholders and holders of Preferred Shares, voting together as a single class. In addition, if at any time dividends on the Fund's outstanding Preferred Shares are unpaid in an amount equal to two full years' dividends thereon, the holders of all outstanding Preferred Shares, voting as a separate class, would be entitled to elect a majority of the Fund's trustees until all dividends in arrears have been paid or declared and set apart for payment.

##### [**Table of Contents**](#toc)
The Fund's Preferred Shares, if any, will be issued pursuant to a Statement that sets forth certain voting and consent rights of the holders of such Shares, including with respect to certain actions that would affect the preferences, rights, or powers of such class or series or the authorization or issuance of any class or series ranking prior to the Preferred Shares. Except as may otherwise be required by law, the Fund's Declaration of Trust requires that (1) the affirmative vote of the holders of at least two-thirds of the Fund's Preferred Shares outstanding at the time, voting as a separate class, would be required to approve any conversion of the Fund from a closed-end to an open-end investment company and (2) the affirmative vote of the holders of at least two-thirds of the outstanding Preferred Shares, voting as a separate class, would be required to approve any plan of reorganization (as such term is used in the 1940 Act) adversely affecting such shares; provided however, that such separate class vote would be a majority vote if the action in question has previously been approved, adopted or authorized by the affirmative vote of two-thirds of the total number of trustees fixed in accordance with the Declaration of Trust or the By-laws. The affirmative vote of the holders of a majority of the outstanding Preferred Shares, voting as a separate class, would be required to approve any action not described in the preceding sentence requiring a vote of security holders under Section 13(a) of the 1940 Act including, among other things, changes in the Fund's investment objective or changes in the investment restrictions described as fundamental policies under "Investment Restrictions" in the SAI. The class or series vote of holders of Preferred Shares described above would in each case be in addition to any separate vote of the requisite percentage of Common Shares and Preferred Shares necessary to authorize the action in question.

The foregoing voting provisions would not apply with respect to any Fund Preferred Shares if, at or prior to the time when a vote was required, such shares have been (1) redeemed or (2) called for redemption and sufficient funds would have been deposited in trust to effect such redemption.

*Redemption, Purchase and Sale of Preferred Shares* 

The terms of the Preferred Shares may provide that they are redeemable by the Fund at certain times, in whole or in part, at the liquidation preference of such share plus accumulated dividends, that the Fund may tender for or purchase Preferred Shares and that the Fund may subsequently resell any shares so tendered for or purchased. Any redemption or purchase of Preferred Shares by the Fund would reduce the leverage applicable to Common Shares, while any resale of such shares by the Fund would increase such leverage.

##### [**Table of Contents**](#toc)
**RIGHTS OFFERINGS** 

The Fund may in the future, and at its discretion, choose to make offerings of Rights to its shareholders to purchase Common Shares. Rights may be issued independently or together with any other offered security and may or may not be transferable by the person purchasing or receiving the rights. In connection with a Rights offering to shareholders, the Fund would distribute certificates or other documentation evidencing the Rights and a prospectus supplement to the Fund's shareholders as of the record date that the Fund sets for determining the shareholders eligible to receive Rights in such Rights offering. Any such future Rights offering will be made in accordance with the 1940 Act and, to the extent such Rights are transferable, will comply with applicable interpretations of the SEC or its staff, as such interpretations may be modified in the future, which currently require that: (i) the Fund's Board of Trustees make a good faith determination that such offering would result in a net benefit to existing shareholders; (ii) the offering fully protects shareholders' preemptive rights and does not discriminate among shareholders (except for the possible effect of not offering fractional rights); (iii) management uses its best efforts to ensure an adequate trading market in the Rights for use by shareholders who do not exercise such Rights; and (iv) the ratio of such transferable Rights offering does not exceed one new share for each three rights held.

The applicable prospectus supplement would describe the following terms of the Rights (to the extent each is applicable) in respect of which this Prospectus is being delivered:

● the period of time the offering would remain open;

● the underwriter or distributor, if any, of the Rights and any associated underwriting fees or discounts applicable to purchases of the Rights;

● the title of such Rights;

● the exercise price for such Rights (or method of calculation thereof);

● the number of such Rights issued in respect of each share;

● the number of Rights required to purchase a single share;

● the extent to which such Rights are transferable and the market on which they may be traded if they are transferable;

● if such Rights are transferable, a discussion regarding
the Board of Trustees' basis for determining that such offering would result in a net benefit to existing shareholders;

● if applicable, a discussion of the material U.S. federal income tax considerations applicable to the issuance or exercise of such Rights;

● the date on which the right to exercise such Rights will commence, and the date on which such right will expire (subject to any extension);

● the extent to which such Rights include an over-subscription privilege with respect to unsubscribed securities and the terms of such over-subscription privilege;

● termination rights the Fund may have in connection with such Rights offering;
and

● any other terms of such Rights, including exercise, settlement and other procedures and limitations relating to the transfer and exercise of such Rights.

A certain number of Rights would entitle the holder of the Right(s) to purchase for cash such number of shares at such exercise price as in each case is set forth in, or be determinable as set forth in, the prospectus supplement relating to the Rights offered thereby. Rights would be exercisable at any time up to the close of business on the expiration date for such Rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised Rights would become void. Upon expiration of the Rights offering and the receipt of payment and the Rights certificate or other appropriate documentation properly executed and completed and duly executed at the corporate trust office of the Rights agent, or any other office indicated in the prospectus supplement, the Common Shares purchased as a result of such exercise will be issued as soon as practicable. To the extent permissible under applicable law, the Fund may determine to offer any unsubscribed offered securities directly to persons other than shareholders, to or through agents, underwriters or dealers or through a combination of such methods, as set forth in the applicable prospectus supplement.

##### [**Table of Contents**](#toc)
**CERTAIN PROVISIONS IN THE DECLARATION OF TRUST AND BY-LAWS** 

*General*. The By-laws of the Fund provide that by becoming a shareholder of the Fund, each shareholder shall be deemed to have agreed to be bound by the terms of the Declaration of Trust and By-laws. However, neither the Declaration of Trust nor the By-laws purport to require the waiver of a shareholder's rights under the federal securities laws.

*Shareholder and Trustee Liability*. Under Massachusetts law, shareholders could, under certain circumstances, be held personally liable for the Fund's obligations. However, the Declaration of Trust contains an express disclaimer of shareholder liability for the Fund's debts or obligations and requires that notice of such limited liability be given in each agreement, obligation or instrument entered into or executed by the Fund or the trustees. The Declaration of Trust further provides for indemnification out of the Fund's assets and property for all loss and expense of any shareholder held personally liable for the Fund's obligations. Thus, the risk of a shareholder incurring financial loss on account of shareholder liability is limited to circumstances in which the Fund would be unable to meet its obligations. The Fund believes that the likelihood of such circumstances is remote.

The Declaration of Trust provides that the Fund's obligations are not binding upon the Fund's trustees individually, but only upon the Fund's assets and property, and that the trustees shall not be liable for errors of judgment or mistakes of fact or law. Nothing in the Declaration of Trust, however, protects a trustee against any liability to which the trustee would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of the trustee's office.

*Anti-Takeover Provisions*. The Declaration of Trust and By-laws include provisions that could limit the ability of other entities or persons to acquire control of the Fund or to convert the Fund to open-end status. The By-laws require the Board of Trustees be divided into three classes with staggered terms. See "Management of the Fund" in the SAI. This provision of the By-laws could delay for up to two years the replacement of a majority of the Board of Trustees. When Preferred Shares are issued, holders of Preferred Shares, voting as a separate class, are entitled to elect two of the Fund's trustees. In addition, the Declaration of Trust requires a vote by holders of at least two-thirds of the Common Shares and, if issued, Preferred Shares, voting together as a single class, except as described below, to authorize (1) a conversion of the Fund from a closed-end to an open-end investment company, (2) a merger or consolidation of the Fund, or a series or class of the Fund, with any corporation, association, trust or other organization or a reorganization of the Fund, or a series or class of the Fund, (3) a sale, lease or transfer of all or substantially all of the Fund's assets (other than in the regular course of the Fund's investment activities), (4) in certain circumstances, a termination of the Fund, or a series or class of the Fund or (5) a removal of trustees by shareholders, and then only for cause, unless, with respect to (1) through (4), such transaction has already been authorized by the affirmative vote of two-thirds of the total number of trustees fixed in accordance with the Declaration of Trust or the By-laws, in which case the affirmative vote of the holders of at least a majority of the Fund's Common Shares and, if issued, Preferred Shares outstanding at the time, voting together as a single class, would be required; provided, however, that where only a particular class or series is affected (or, in the case of removing a trustee, when the trustee has been elected by only one class), only the required vote by the applicable class or series will be required. However, approval of shareholders would not be required for any transaction, whether deemed a merger, consolidation, reorganization or otherwise whereby the Fund issues shares in connection with the acquisition of assets (including those subject to liabilities) from any other investment company or similar entity. In the case of the conversion of the Fund from a closed-end investment company to an open-end investment company, or in the case of any of the foregoing transactions constituting a plan of reorganization that adversely affects the holders of any outstanding Preferred Shares, the action in question also would require the affirmative vote of the holders of at least two-thirds of the Preferred Shares outstanding at the time, voting as a separate class, unless such transaction has already been authorized by the affirmative vote of two-thirds of the total number of trustees fixed in accordance with the Declaration of Trust or the By-laws, in which case the affirmative vote of the holders of at least a majority of the Fund's Preferred Shares outstanding at the time would be required. None of the foregoing provisions may be amended except by the vote of at least two-thirds of the Common Shares and any Preferred Shares voting together as a single class. The votes required to approve the conversion of the Fund from a closed-end to an open-end investment company or to approve transactions constituting a plan of reorganization which adversely affects the holders of preferred shares are higher than those required by the 1940 Act. The Board of Trustees believes that the provisions of the Declaration of Trust relating to such higher votes are in the best interest of the Fund and its shareholders.

##### [**Table of Contents**](#toc)
*Procedural Requirements on Derivative Actions, Exclusive Jurisdiction and Jury Trial Waiver*. The By-laws of the Fund contain certain provisions affecting potential shareholder claims against the Fund, including procedural requirements for derivative actions, an exclusive forum provision, and the waiver of shareholder rights to a jury trial. Massachusetts is considered a "universal demand" state, meaning that under Massachusetts corporate law a shareholder must make a demand on the company before bringing a derivative action (i.e., a lawsuit brought by a shareholder on behalf of the company). The By-laws of the Fund provide detailed procedures for the bringing of derivative actions by shareholders which are modeled on the substantive provisions of the Massachusetts corporate law derivative demand statute. The procedures are intended to permit legitimate inquiries and claims while avoiding the time, expense, distraction, and other harm that can be caused to the Fund or its shareholders as a result of spurious shareholder demands and derivative actions. Among other things, these procedures:

● provide that before bringing a derivative action, a shareholder must make a written demand to the Fund;

● establish a 90-day review period, subject to extension in certain circumstances, for the Board of Trustees to evaluate the shareholder's demand;

● establish a mechanism for the Board of Trustees to submit the question of whether to maintain a derivative action to a vote of shareholders;

● provide that if the Fund does not notify the requesting shareholder of the rejection of the demand within the applicable review period, the shareholder may commence a derivative action;

● establish bases upon which a trustee will not be considered to be not independent for purposes of evaluating a derivative demand; and

● provide that if the trustees who are independent for purposes of considering a shareholder demand determine in good faith within the applicable review period that the maintenance of a derivative action is not in the
best interest of the Fund, the shareholder shall not be permitted to maintain a derivative action unless the shareholder first sustains the burden of proof to the court that the decision of the trustees not to pursue the requested action was not a
good faith exercise of their business judgment on behalf of the Fund.

These procedures may be more restrictive than procedures for bringing derivative suits applicable to other investment companies.

The By-laws also require that actions by shareholders against the Fund, except for actions under the U.S. federal securities laws, be brought only in a certain federal court in Massachusetts, or if not permitted to be brought in federal court, then in the Business Litigation Session of the Massachusetts Superior Court in Suffolk County (the "Exclusive Jurisdictions"), and that the right to jury trial be waived to the fullest extent permitted by law. Other investment companies may not be subject to similar restrictions. The designation of Exclusive Jurisdictions may make it more expensive for a shareholder to bring a suit than if the shareholder were permitted to select another jurisdiction. In the event a shareholder selects another jurisdiction to bring its suit and the venue for such suit is subsequently changed back to an Exclusive Jurisdiction through the legal process, then such shareholder shall be required to reimburse all expenses incurred by the Fund or any other person in effecting such change of venue back to the Exclusive Jurisdiction. Also, the designation of Exclusive Jurisdictions and the waiver of jury trials limit a shareholder's ability to litigate a claim in the jurisdiction and in a manner that may be more favorable to the shareholder. It is possible that a court may choose not to enforce these provisions of the Fund's By-laws.

##### [**Table of Contents**](#toc)
*Preemptive Rights*. The Declaration of Trust provides that Common Shareholders shall have no right to acquire, purchase or subscribe for any shares or investments of the Fund, other than such right, if any, as the Fund's Board of Trustees in its discretion may determine. As of the date of this Prospectus, no preemptive rights have been granted by the Board of Trustees.

Reference should be made to the Declaration of Trust and By-laws on file with the SEC for the full text of these provisions.

**REPURCHASE OF FUND SHARES; CONVERSION TO OPEN-END FUND** 

The Fund is a closed-end investment company and as such its shareholders will not have the right to cause the Fund to redeem their shares. Instead, the Common Shares will trade in the open market at a price that will be a function of several factors, including dividend levels (which are in turn affected by expenses), NAV, call protection, dividend stability, portfolio credit quality, relative demand for and supply of such shares in the market, general market and economic conditions and other factors. Because shares of closed-end investment companies may frequently trade at prices lower than NAV, the Fund's Board of Trustees has currently determined that, at least annually, it will consider action that might be taken to reduce or eliminate any material discount from NAV in respect of Common Shares, which may include the repurchase of such shares in the open market or in private transactions, the making of a tender offer for such shares at NAV, or the conversion of the Fund to an open-end investment company. The Fund cannot assure you that its Board of Trustees will decide to take any of these actions, or that share repurchases or tender offers will actually reduce market discount.

If the Fund converted to an open-end investment company, it would be required to redeem all Preferred Shares, if any, then outstanding (requiring in turn that it liquidate a portion of its investment portfolio), and the Common Shares would no longer be listed on the NYSE or elsewhere and it would likely have to significantly reduce any leverage it is then employing, which may require a repositioning of its investment portfolio, which may in turn generate substantial transaction costs, which would be borne by Common Shareholders, and may adversely affect Fund performance and Fund distributions. In contrast to a closed-end investment company, shareholders of an open-end investment company may require the company to redeem their shares at any time (except in certain circumstances as authorized by the 1940 Act or the rules thereunder) at their NAV, less any redemption charge that is in effect at the time of redemption. The Fund currently expects that any such redemptions would be made in cash. The Fund may charge sales or redemption fees upon conversion to an open-end fund. In order to avoid maintaining large cash positions or liquidating favorable investments to meet redemptions, open-end investment companies typically engage in a continuous offering of their shares. Open-end investment companies are thus subject to periodic asset in-flows and out-flows that can complicate portfolio management. The Board of Trustees may at any time propose conversion of the Fund to an open-end investment company depending upon its judgment as to the advisability of such action in light of circumstances then prevailing.

Before deciding whether to take any action if the Common Shares trade below NAV, the Fund's Board of Trustees would consider all relevant factors, including the extent and duration of the discount, the liquidity of the Fund's portfolio, the impact of any action that might be taken on the Fund or its shareholders, and market considerations. Based on these considerations, even if the Fund's shares should trade at a discount, the Board of Trustees may determine that, in the interest of the Fund and its shareholders, no action should be taken.

##### [**Table of Contents**](#toc)
**TAX MATTERS** 

The following information is meant as a general summary for U.S. Common Shareholders. Please see the SAI for additional information. Investors should rely on their own tax adviser for advice about the particular federal, state and local tax consequences to them of investing in the Fund. This summary does not discuss the tax consequences of an investment in Rights or Preferred Shares. The tax consequences of such an investment will be discussed in the relevant prospectus supplement.

The Fund has elected and intends to qualify each year to be treated as a RIC under Subchapter M of the Internal Revenue Code. In order to qualify for treatment as a RIC, the Fund must satisfy certain requirements regarding the sources of its income, the diversification of its assets and the distribution of its income. Provided that the Fund timely distributes its income it is not expected to be subject to federal income tax. Dividends paid out of the Fund's investment company taxable income (which includes dividends the Fund receives, interest income and net short-term capital gain) will generally be taxable to shareholders as ordinary income, except as described below with respect to qualified dividend income. Net capital gain distributions (the excess of net long-term capital gain over net short-term capital loss) are generally taxable at rates applicable to long-term capital gains regardless of how long a shareholder has held its shares. Long-term capital gains for non-corporate shareholders are currently taxable at a maximum federal income tax rate of 20%. In addition, certain individuals, estates and trusts are subject to a 3.8% Medicare tax on net investment income, including net capital gains and other taxable dividends. Corporate shareholders are taxed on capital gain at the same rates as apply to ordinary income. Distributions derived from qualified dividend income and received by a non- corporate shareholder will be taxed at the rates applicable to long-term capital gain. In order for some portion of the dividends received by a shareholder to be qualified dividend income, the Fund must meet certain holding period and other requirements with respect to the dividend-paying stocks in its portfolio and the non-corporate shareholder must meet certain holding period and other requirements with respect to its shares of the Fund. Taxable distributions are taxable whether or not such distributions are reinvested in the Fund. Dividend distributions may be subject to state and local taxation, depending on a shareholder's situation. The Fund's investment strategies may significantly limit its ability to make distributions eligible to be reported as qualified dividend income or for the dividends-received deduction for corporate shareholders. While the Fund may invest in municipal securities the interest income from which is exempt from regular federal income tax, the Fund does not expect to satisfy the requirements to pay exempt-interest dividends to shareholders.

If the Fund's total distributions exceed both the current taxable year's earnings and profits and accumulated earnings and profits from prior years, the excess generally will be treated as a tax-free return of capital up to and including the amount of a shareholder's tax basis in its shares of the Fund, and thereafter as capital gain. Upon a sale of shares of the Fund, the amount, if any, by which the sales price exceeds the basis in the shares of the Fund is gain subject to federal income tax. Because a return of capital reduces basis in the shares of the Fund, it will increase the amount of gain or decrease the amount of loss on a shareholder's subsequent disposition of the shares of the Fund.

As a regulated investment company, the Fund will not be subject to federal income tax in any taxable year provided that it meets certain distribution requirements. The Fund may retain for investment some (or all) of its net capital gain. If the Fund retains any net capital gain or investment company taxable income, it will be subject to tax at the regular corporate rate on the amount retained. If the Fund retains any net capital gain, it may designate the retained amount as undistributed capital gains in a notice to its shareholders who if subject to federal income tax on long-term capital gains, (i) will be required to include in income for federal income tax purposes, as long-term capital gain, their share of such undistributed amount; (ii) will be entitled to credit their proportionate shares of the federal income tax paid by the Fund on such undistributed amount against their federal income tax liabilities, if any; and (iii) may claim refunds to the extent the credit exceeds such liabilities. For federal income tax purposes, the basis of shares owned by a shareholder of the Fund will be increased by an amount equal to the difference between the amount of undistributed capital gains included in the shareholder's gross income and the tax deemed paid by the shareholder under clause (ii) of the preceding sentence. Unless a shareholder's investment in the Fund is through a tax-exempt entity or tax deferred retirement account, such as a 401(k) plan, the shareholder will normally have to pay federal income taxes, and any applicable state or local taxes, on the dividends and other distributions the shareholder receives from the Fund, whether it takes the distributions in cash or reinvest them in additional shares.

If the Fund utilizes leverage through borrowings, or otherwise, asset coverage limitations imposed by the 1940 Act as well as additional restrictions that may be imposed by certain lenders on the payment of dividends or distributions potentially could limit or eliminate the Fund's ability to make distributions on its common shares and/or preferred shares, if any, until the asset coverage is restored. These limitations could prevent the Fund from distributing at least 90% of its investment company taxable income as is required under the Code and therefore might jeopardize the Fund's qualification as a regulated investment company and/or might subject the Fund to a nondeductible 4% federal excise tax. The Fund endeavors to avoid restrictions on its ability to distribute dividends.

##### [**Table of Contents**](#toc)
Dividends declared by the Fund in October, November or December, payable to shareholders of record in such a month, and paid during the following January will be treated as having been received by shareholders in the year the distributions were declared.

Investments by the Fund in zero coupon or other discount securities will result in income to the Fund equal to a portion of the excess of the face value of the securities over their issue price (the "original issue discount" or "OID") each year that the securities are held, even though the Fund may receive no cash interest payments or may receive cash interest payments that are less than the income recognized for tax purposes. In addition, any market discount recognized on a market discount bond is taxable as ordinary income. A market discount bond is a bond acquired in the secondary market at a price below redemption value, or below adjusted issue price if issued with original issue discount. Absent an election by the Fund to include the market discount in income as it accrues, gain on the Fund's disposition of such an obligation will be treated as ordinary income rather than capital gain to the extent of the accrued market discount. Because the income required to be recognized by the Fund as a result of the OID and/or market discount rules may not be matched by a corresponding cash payment to the Fund, the Fund may be required to borrow money or dispose of securities to be able to make distributions to its shareholders in order to qualify for treatment as a RIC and eliminate taxes at the Fund level.

Each shareholder will receive an annual statement summarizing the U.S. federal income tax status of all distributions.

Unless your investment in the Fund is through a tax-exempt entity or tax deferred retirement account, the repurchase, sale or exchange of Common Shares normally will result in capital gain or loss to Common Shareholders who hold their shares as capital assets. Generally, a shareholder's gain or loss will be long-term capital gain or loss if the shares have been held for more than one year even though the increase in value in such Common Shares may be at least partly attributable to tax-exempt interest income. For non-corporate taxpayers, long-term capital gains are currently taxed at rates of up to 20%. Short-term capital gains and other ordinary income are taxed to non-corporate taxpayers at ordinary income rates. If a shareholder sells or otherwise disposes of Common Shares before holding them for six months, any loss on the sale or disposition will be treated as a long-term capital loss to the extent of any amounts treated as distributions to the common shareholder of long-term capital gain (including any amount credited to the common shareholder as undistributed capital gain). Any loss realized by a shareholder on the disposition of shares held 6 months or less is disallowed to the extent of the amount of exempt-interest dividends received by the shareholder with respect to Common Shares. Any loss realized on a sale or exchange of shares of the Fund will be disallowed to the extent those shares of the Fund are replaced by substantially identical shares of the Fund (including shares acquired by reason of participation in the Plan) within a period of 61 days beginning 30 days before and ending 30 days after the date of disposition of the original shares, or to the extent the shareholder enters into a contract or option to repurchase shares within such period. In that event, the basis of the replacement shares of the Fund will be adjusted to reflect the disallowed loss.

The Fund may be required to withhold (as "backup withholding") U.S. federal income tax for distributions (including exempt-interest dividends) and repurchase proceeds payable to a shareholder if the shareholder fails to provide the Fund with the shareholder's correct taxpayer identification number or to make required certifications, or if the shareholder has been notified by the IRS that the shareholder is subject to backup withholding. The backup withholding rate is 24%. Backup withholding is not an additional tax; rather, it is a way in which the IRS ensures it will collect taxes otherwise due. Any amounts withheld may be credited against a shareholder's U.S. federal income tax liability.

The Fund may invest in other instruments the U.S. federal income tax treatment of which is uncertain or subject to re-characterization by the IRS. To the extent the tax treatment of such instruments or their income differs from the tax treatment expected by the Fund, it could affect the timing or character of income recognized by the Fund, requiring the Fund to purchase or sell instruments, or otherwise change its portfolio, in order to comply with the tax rules applicable to RICs under the Code. Common Shareholders may be subject to state, local and foreign taxes on their Fund distributions. Shareholders are advised to consult their own tax advisers with respect to the particular consequences to them of an investment in the Fund.

**CUSTODIAN AND TRANSFER AGENT** 

The custodian of the assets of the Fund is State Street Bank and Trust Company, located at One Congress Street, Suite 1, Boston, Massachusetts 02114-2016 (the "Custodian"). The Custodian performs custodial, fund accounting and portfolio accounting services. The Fund's transfer, shareholder services and dividend paying agent with respect to the Fund's Common Shares is Computershare Inc. and Computershare Trust Company, N.A., located at 150 Royall Street, Canton, Massachusetts 02021. The transfer agent, tender and dividend paying agent and calculation agent for any Preferred Shares, will be identified in the applicable prospectus supplement.

##### [**Table of Contents**](#toc)
**INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

KPMG LLP ("KPMG"), an independent registered public accounting firm, served as independent registered public accounting firm to the Fund for the fiscal year ended December 31, 2024. The principal business address of KPMG is 200 East Randolph Street, Chicago, IL 60601.

PricewaterhouseCoopers LLP ("PwC"), an independent registered public accounting firm, has been engaged to serve as independent registered public accounting firm to the Fund for the fiscal year ended December 31, 2025 and the current fiscal year. The principal business address of PwC is One North Wacker Drive, Chicago, IL 60606.

**LEGAL MATTERS** 

Certain legal matters in connection with the offering will be passed upon for the Fund by Stradley Ronon Stevens & Young, LLP, located at 2005 Market Street, Suite 2600, Philadelphia, PA 19103. Stradley Ronon Stevens & Young, LLP may rely as to certain matters of Massachusetts law on the opinion of Morgan, Lewis & Bockius LLP. Any additional legal opinions will be described in a prospectus supplement.

**AVAILABLE INFORMATION** 

The Fund is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the 1940 Act and is required to file reports, proxy statements and other information with the SEC. Reports, proxy statements, and other information about the Fund can be inspected at the offices of the NYSE.

This Prospectus does not contain all of the information in the Fund's Registration Statement, including amendments, exhibits, and schedules. Statements in this Prospectus about the contents of any contract or other document are not necessarily complete and, in each instance, reference is made to the copy of the contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified in all respects by this reference.

Additional information about the Fund and the Securities can be found in the Fund's Registration Statement (including amendments, exhibits, and schedules) on Form N-2 filed with the SEC. The SEC maintains a website (http://www.sec.gov) that contains the Fund's Registration Statement, other documents incorporated by reference, and other information the Fund has filed electronically with the SEC, including proxy statements and reports filed under the Exchange Act.

**INCORPORATION BY REFERENCE** 

The documents listed below, and any reports and other documents subsequently filed with the SEC pursuant to Section 30(b)(2) of the 1940 Act and Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering will be incorporated by reference into this Prospectus and deemed to be part of this Prospectus from the date of the filing of such reports and documents:

● The Fund's [SAI](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001539337/000199937126001398/jri-n2a_012126.htm#toc780884_25) , dated January 23, 2026; and

● The Fund's [<u>annual report</u>](http://www.sec.gov/Archives/edgar/data/1539337/000119312525049513/d903508dncsr.htm) on Form N-CSR for the fiscal year ended December 31, 2024.

● The description of the Common Shares contained in the Fund's [Registration Statement](http://www.sec.gov/Archives/edgar/data/1539337/000119312512129396/d269076d8a12b.htm) on Form 8-A (File No. 001-35472) filed with the SEC on March 23, 2012, including any amendment or report
filed for the purpose of updating such description prior to the termination of the offering registered hereby.

The information incorporated by reference is considered to be part of this Prospectus, and later information that the Fund files with the SEC will automatically update and supersede this information. Incorporated materials not delivered with the Prospectus may be obtained, without charge, by calling (800) 257-8787, by writing to the Fund at 333 West Wacker Drive, Chicago, Illinois 60606, or from the Fund's website (<u>http://www.nuveen.com</u>).